

POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND
PHARMACEUTICAL COMPOSITIONS CONTAINING THEM


BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

[0001] Polymorphs of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Also, pharmaceutical compositions comprising polymorphs of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the polymorphs are provided herein.

DESCRIPTION OF THE STATE OF THE ART

[0002] *N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine (also called "ARRY-380"), which has the structure:



is a selective ErbB2 (HER2) inhibitor described in WO 2007/059257, which is incorporated by reference in its entirety. *N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine has been tested in human clinical trials for hyperproliferative diseases, particularly cancer (see Koch, Kevin. "ARRY-380: A Selective, Oral HER2 Inhibitor for the Treatment of Solid Tumors." American Association of Cancer Research 102nd Annual Meeting, April 3, 2011; which may also be found at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment462.pdf).

[0003] Polymorphism is the occurrence of different crystalline forms of a single compound and it is a property of some compounds and complexes. Thus, polymorphs are distinct solids sharing the same molecular formula, yet each polymorph may have distinct solid state physical properties. Therefore, a single compound may give rise to a variety of polymorphic forms where each form has different and distinct solid state physical properties, such as different solubility profiles, melting point temperatures, flowability, dissolution rates and/or different X-ray diffraction peaks. These practical physical characteristics are influenced by the conformation and orientation of molecules in the unit cell, which defines a particular polymorphic form of a substance. Due to the possibility of variable solubility of each

polymorph, identifying the existence of pharmaceutical polymorphs is essential for providing pharmaceuticals with predictable solubility profiles. It is desirable to investigate all solid state forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in a laboratory by X-ray diffraction spectroscopy, such as X-ray powder diffraction ("XRPD"), and by other methods, such as infrared spectrometry. Additionally, polymorphic forms of the same drug substance or active pharmaceutical ingredient can be administered by itself or formulated as a drug product (pharmaceutical composition) and are well known in the pharmaceutical art to affect, for example, the solubility, stability, flowability, tractability and compressibility of drug substances and the safety and efficacy of drug products. For more, see Hilfiker, Rolf (ed.), Polymorphism in the Pharmaceutical Industry. Weinheim, Germany: Wiley-VCH 2006.

[0004] The discovery of new polymorphic forms of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical product. It has now been surprisingly found that new crystalline forms of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine exist.

SUMMARY OF THE INVENTION

[0005] Polymorphic forms of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are described herein, including Forms A, B, C, D, E, F, G, H, I, J, K, L, M, N, O and P. Additionally, amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is described herein. Accordingly, the compounds are useful in the treatment of hyperproliferative diseases, such as cancer.

[0006] Another aspect provides methods of preventing or treating a disease or disorder modulated by ErbB2, comprising administering to a mammal in need of such treatment an effective amount of a compound described herein.

[0007] Another aspect provides methods of preventing or treating cancer, comprising administering to a mammal in need of such treatment an effective amount of a compound described herein, alone or in combination with one or more additional compounds having anti-cancer properties.

[0008] Another aspect provides a method of treating a hyperproliferative disease in a mammal comprising administering a therapeutically effective amount of a compound described herein to the mammal.

[0009] Another aspect provides the use of a compound of this invention in the manufacture of a medicament for the treatment of a hyperproliferative disease.

[0010] Another aspect provides compounds described herein for use in the treatment of cancer.

[0011] Another aspect provides a pharmaceutical composition comprising a compound described herein, and a pharmaceutically acceptable carrier or excipient.

[0012] Another aspect provides processes for preparing compounds described herein.

BRIEF DESCRIPTION OF THE FIGURES

[0013] Figure 1 shows a characteristic XRPD scan of Form A.

[0014] Figure 2 shows a characteristic XRPD scan of Form B Methanol.

[0015] Figure 3 shows a characteristic XRPD scan of Form B Ethanol.

[0016] Figure 4 shows a characteristic XRPD scan of Form B Isopropyl Alcohol.

[0017] Figure 5 shows a characteristic XRPD scan of Form B Acetonitrile.

[0018] Figure 6 shows a characteristic XRPD scan of Form B Acetone.

[0019] Figure 7 shows a characteristic XRPD scan of Form B Dichloromethane.

[0020] Figure 8 shows a characteristic XRPD scan of Form B Tetrahydrofuran.

[0021] Figure 9 shows a characteristic XRPD scan of Form B Anhydrous.

[0022] Figure 10 shows a characteristic XRPD scan of Form C.

[0023] Figure 11 shows a characteristic XRPD scan of Form D Ethyl Acetate.

[0024] Figure 12 shows a characteristic XRPD scan of Form D Dioxane.

[0025] Figure 13 shows a characteristic XRPD scan of Form D Acetone.

[0026] Figure 14 shows a characteristic XRPD scan of Form D Propyl Acetate.

[0027] Figure 15 shows a characteristic XRPD scan of Form E.

[0028] Figure 16 shows a characteristic XRPD scan of Form F.

[0029] Figure 17 shows a characteristic XRPD scan of Form G hemi-Tetrahydrofuran.

[0030] Figure 18 shows a characteristic XRPD scan of Form G mono-Tetrahydrofuran.

[0031] Figure 19 shows a characteristic XRPD scan of Form G Isopropyl Acetate.

[0032] Figure 20 shows a characteristic XRPD scan of Form G Methyl Isobutyl Ketone.

- [0033] Figure 21 shows a characteristic XRPD scan of Form H.
- [0034] Figure 22 shows a characteristic XRPD scan of Form I.
- [0035] Figure 23 shows a characteristic XRPD scan of Form J.
- [0036] Figure 24 shows a characteristic XRPD scan of Form K.
- [0037] Figure 25 shows a characteristic XRPD scan of Form L.
- [0038] Figure 26 shows a characteristic XRPD scan of Form M.
- [0039] Figure 27 shows a characteristic XRPD scan of Form N.
- [0040] Figure 28 shows a characteristic XRPD scan of Form O.
- [0041] Figure 29 shows a characteristic XRPD scan of Form P.
- [0042] Figure 30 shows a characteristic XRPD scan of amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
- [0043] Figure 31 shows a characteristic differential scanning calorimetry ("DSC") scan of Form A.
- [0044] Figure 32 shows a characteristic DSC scan of Form B Methanol.
- [0045] Figure 33 shows a characteristic DSC scan of Form B Ethanol.
- [0046] Figure 34 shows a characteristic DSC scan of Form B Isopropyl Alcohol.
- [0047] Figure 35 shows a characteristic DSC scan of Form B Acetonitrile.
- [0048] Figure 36 shows a characteristic DSC scan of Form B Acetone.
- [0049] Figure 37 shows a characteristic DSC scan of Form B Dichloromethane.
- [0050] Figure 38 shows a characteristic DSC scan of Form B Tetrahydrofuran.
- [0051] Figure 39 shows a characteristic DSC scan of Form C.
- [0052] Figure 40 shows a characteristic DSC scan of Form D Ethyl Acetate.
- [0053] Figure 41 shows a characteristic DSC scan of Form D Dioxane.
- [0054] Figure 42 shows a characteristic DSC scan of Form D Acetone.
- [0055] Figure 43 shows a characteristic DSC scan of Form D Propyl Acetate.
- [0056] Figure 44 shows a characteristic DSC scan of Form E.
- [0057] Figure 45 shows a characteristic DSC scan of Form F.
- [0058] Figure 46 shows a characteristic DSC scan of Form G hemi-Tetrahydrofuran.
- [0059] Figure 47 shows a characteristic DSC scan with a thermal gravimetric analysis ("TGA") overlay of Form G mono-Tetrahydrofuran.
- [0060] Figure 48 shows a characteristic DSC scan of Form G Isopropyl Acetate.
- [0061] Figure 49 shows a characteristic DSC scan of Form G Methyl Isobutyl Ketone.

- [0062] Figure 50 shows a characteristic DSC scan of Form H.
- [0063] Figure 51 shows a characteristic DSC scan of Form I.
- [0064] Figure 52 shows a characteristic DSC scan of Form K.
- [0065] Figure 53 shows a characteristic DSC scan of Form L.
- [0066] Figure 54 shows a characteristic DSC scan of Form M.
- [0067] Figure 55 shows a characteristic DSC scan of Form N.
- [0068] Figure 56 shows a characteristic DSC scan of Form O.
- [0069] Figure 57 shows a characteristic DSC scan of Form P.
- [0070] Figure 58 shows a characteristic mDSC scan of amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.

DETAILED DESCRIPTION OF THE INVENTION

[0071] Reference will now be made in detail to certain embodiments, examples of which are illustrated in the accompanying structures and formulas. While enumerated embodiments will be described, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.

DEFINITIONS

[0072] Some alkyl moieties have been abbreviated, for example, methyl ("Me") and ethyl ("Et"). The abbreviations are sometimes used in conjunction with elemental abbreviations and chemical structures, for example, methanol ("MeOH") or ethanol ("EtOH"). Additional abbreviations used throughout the application may include, for example, acetate ("Ac"), acetonitrile ("ACN"), dichloromethane ("DCM"), dimethoxyethane ("DME"), ethyl acetate ("EtOAc"), isopropyl alcohol ("IPA"), methyl acetate ("MeOAc"), methyl isobutyl ketone ("MIBK"), methyl *tert*-butyl ether ("MTBE"), sodium carboxymethyl cellulose ("NaCMC") and tetrahydrofuran ("THF").

[0073] The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it

modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%. In regard to 2θ degrees, the term about means $\pm$ 0.2 degrees for polymorphs and $\pm$ 0.6 degrees for isomorphous polymorphs, unless stated otherwise.

[0074] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by abnormal or unregulated cell growth. A "tumor" comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (*e.g.*, epithelial squamous cell cancer), lung cancer including small cell lung cancer, non-small cell lung cancer ("NSCLC"), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, brain, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, skin cancer, including melanoma, as well as head and neck cancer.

[0075] The term "mammal" means a warm-blooded animal that has or is at risk of developing a disease described herein and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans.

[0076] The phrase "pharmaceutically acceptable" indicates that the substance or composition is compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.

[0077] The phrase "substantially pure" means the polymorphic form or amorphous material includes less than about 15% by weight of impurities, including other polymorphic forms. In certain embodiments, the substantially pure polymorphic form or amorphous material includes less than about 10% by weight of impurities, including other polymorphic forms. In certain embodiments, the substantially pure polymorphic form or amorphous material includes less than about 5% by weight of impurities, including other polymorphic forms. In certain embodiments, the substantially pure polymorphic form or amorphous material includes less than about 1% by weight of impurities, including other polymorphic forms.

[0078] The phrases "therapeutically effective amount" or "effective amount" mean an amount of a compound described herein that, when administered to a mammal in need of such treatment, sufficient to (i) treat or prevent the particular disease, condition, or disorder, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein. The amount of a compound that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (*e.g.*, weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art.

[0079] The terms "treat" or "treatment" refer to therapeutic, prophylactic, palliative or preventative measures. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (*i.e.*, not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

POLYMORPHS

[0080] Provided herein are polymorphs of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine freebase, designated Forms A, B, C, D, E, F, G, H, I, J, K, L, M, N, O and P. Also, provided herein is amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. Processes for preparing the polymorphs, and pharmaceutical compositions thereof that are potentially useful in the treatment of diseases, conditions and/or disorders modulated by ErbB2 are also provided.

[0081] Many of the polymorphs described herein are solvates. However, some of the polymorphs are not solvates, but exist, for example, as anhydrous forms. Also, some of the polymorphs are isomorphic solvate polymorphs (or solvatomorph), which crystallize in the same space group with slight variation of cell parameters and comprise chemically related structures but different elemental composition. In this case, the variation in chemical composition among the isomorphs arises from incorporation of different water/solvent molecules. Consequently, the isomorphs display similar but non-identical XRPD patterns. For more information on isomorphic polymorphs, see Hilfiker, *supra*.

Form A

[0082] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A is provided. Form A can be distinguished by the XRPD diffraction in Figure 1 and/or peak assignments of the XRPD diffraction of Figure 1 in Table 1.

[0083] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 20.3 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 20.278 is provided.

[0084] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 19.1, 20.3, 21.9, 23.1 and 25.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 19.138, 20.278, 21.863, 23.139 and 25.202 is provided.

[0085] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 16.9, 19.1, 20.3, 21.1, 21.9, 23.1 and 25.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 16.94, 19.138, 20.278, 21.16, 21.863, 23.139 and 25.202 is provided.

[0086] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 12.8, 13.6, 16.3, 16.9, 19.1, 19.4, 20.3, 21.1, 21.9, 23.1, 24.5 and 25.2 is provided. In a

further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 12.78, 13.637, 16.3, 16.94, 19.138, 19.44, 20.278, 21.16, 21.863, 23.139, 24.519 and 25.202 is provided.

[0087] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A which has an XRPD diffraction pattern substantially the same as Figure 1 is provided.

[0088] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 1 is provided.

[0089] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A which is characterized by endotherms at about 203.7°C and 240.0°C is provided.

[0090] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A which is characterized by a DSC scan substantially the same as Figure 31 is provided.

[0091] \Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 1:1 EtOH:water; and

(b) recrystallizing the solid to prepare Form A.

[0092] In certain embodiments, the mixture in Step (a) is heated. In a further embodiment, the mixture in Step (a) is heated to about 50°C.

Form B

[0093] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-

4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B is provided. Form B forms isomorphic solvates. Form B can be distinguished by the representative XRPD diffraction in Figures 2 to 9 and/or representative peak assignments of the XRPD diffraction of Figures 2 to 9 in Tables 2 to 9.

[0094] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.3) 9.9 and 25.5 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.9 and 25.5 is provided.

[0095] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.3) 9.9, 16.9, 18.0, 20.7 and 25.5 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.9, 16.9, 18.0, 20.7 and 25.5 is provided.

[0096] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.3) 8.4, 9.9, 13.4, 16.9, 18.0, 20.7, 21.2, 24.7 and 25.5 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.4, 9.9, 16.9, 18.0, 20.7, 21.2 and 25.5 is provided.

[0097] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B comprising:

(a1) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E with a solvent selected from MeOH, or

(a2) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from MeOH, acetone and DCM, or

(a3) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C/G mixture with a solvent selected from EtOH, or

(a4) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A with a solvent selected from IPA,

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and the solvent, and

(c) recrystallizing the solid to prepare Form B; or

(d1) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and ACN, or

(d2) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and THF, and

(e) recrystallizing the solid to prepare Form B; or

(f) heating *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, and

(g) recovering the solid to prepare Form B.

[0098] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a2) or (a4) to reflux.

[0099] In certain embodiments, the solution in Step (b) is created by using EtOH as the solvent and heating the mixture of Step (a3) to about 70°C.

[00100] In certain embodiments, the heating in Step (f) is done at about 100 to about 200°C.

[00101] In certain embodiments, the solvent in Step (a2) is selected from acetone and DCM

[00102] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (d1).

[00103] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol is provided. Form B Methanol can be distinguished by the XRPD diffraction in Figure 2 and/or peak assignments of the XRPD diffraction of Figure 2 in Table 2.

[00104] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 10.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 9.98 is provided.

[00105] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.5, 10.0, 13.4, 17.0 and 25.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.46, 9.98, 13.438, 16.981 and 25.519 is provided.

[00106] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.5, 10.0, 13.4, 17.0, 18.0, 20.8, 24.7 and 25.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.46, 9.98, 13.438, 16.981, 18.042, 20.799, 24.72 and 25.519 is provided.

[00107] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.5, 10.0, 13.4, 15.8, 17.0, 18.0, 19.7, 20.8, 21.1, 21.6, 23.2, 24.7 and 25.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.46, 9.98, 13.438, 15.802, 16.981, 18.042, 19.72, 20.799, 21.143, 21.622, 23.161, 24.72 and 25.519 is provided.

[00108] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol which has an XRPD diffraction pattern substantially the same as Figure 2 is provided.

[00109] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol which is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) substantially the same as Table 2 is provided.

[00110] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol which is characterized by an endotherm at about 226.8°C is provided.

[00111] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol which is characterized by a DSC scan substantially the same as Figure 32 is provided.

[00112] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol comprising:

[00113] (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine with MeOH;

[00114] (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MeOH; and

[00115] (c) recrystallizing the solid to prepare Form B Methanol.

[00116] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

[00117] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a).

[00118] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol is provided. Form B Ethanol can be distinguished by the XRPD diffraction in Figure 3 and/or peak assignments of the XRPD diffraction of Figure 3 in Table 3.

[00119] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 25.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 25.4 is provided.

[00120] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.9, 13.3, 20.7, 24.6 and 25.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.859, 13.3, 20.718, 24.621 and 25.419 is provided.

[00121] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$

0.2) 9.9, 13.3, 16.9, 17.9, 19.6, 20.7, 21.5, 23.1, 24.6 and 25.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.859, 13.3, 16.862, 17.94, 19.602, 20.718, 21.502, 23.08, 24.621 and 25.419 is provided.

[00122] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol which has an XRPD diffraction pattern substantially the same as Figure 3 is provided.

[00123] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 3 is provided.

[00124] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol which is characterized by an endotherm at about 224.8°C is provided.

[00125] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol which is characterized by a DSC scan substantially the same as Figure 33 is provided.

[00126] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol comprising:

[00127] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C/G mixture with EtOH;

[00128] (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and EtOH; and

[00129] (c) recrystallizing the solid to prepare Form B Ethanol.

[00130] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a) to about 70°C.

[00131] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol is provided. Form B Isopropyl Alcohol can be distinguished by the XRPD diffraction in Figure 4 and/or peak assignments of the XRPD diffraction of Figure 4 in Table 4.

[00132] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.9 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.88 is provided.

[00133] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.8, 16.9, 17.9, 20.6 and 25.1 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.78, 16.88, 17.899, 20.6 and 25.082 is provided.

[00134] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.8, 13.2, 16.9, 17.9, 20.6, 25.1 and 25.3 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.78, 13.201, 16.88, 17.899, 20.6, 25.082 and 25.362 is provided.

[00135] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol, characterized by XRPD diffraction peaks at about

(2θ degrees $\pm$ 0.2) 8.3, 9.8, 13.2, 16.9, 17.9, 20.6, 21.2, 23.0, 24.2, 24.6, 25.1 and 25.3 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.283, 9.78, 13.201, 16.88, 17.899, 20.6, 21.202, 22.981, 24.198, 24.582, 25.082 and 25.362 is provided.

[00136] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol which has an XRPD diffraction pattern substantially the same as Figure 4 is provided.

[00137] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 4 is provided.

[00138] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol which is characterized by an endotherm at about 222.3°C is provided.

[00139] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol which is characterized by a DSC scan substantially the same as Figure 34 is provided.

[00140] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol comprising:

[00141] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A with IPA;

[00142] (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and IPA; and

[00143] (c) recrystallizing the solid to prepare Form B Isopropyl Alcohol.

[00144] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

[00145] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile is provided. Form B Acetonitrile can be distinguished by the XRPD diffraction in Figure 5 and/or peak assignments of the XRPD diffraction of Figure 5 in Table 5.

[00146] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 25.7 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 25.661 is provided.

[00147] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 10.0, 13.5, 16.9, 24.9 and 25.7 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.98, 13.46, 16.921, 24.899 and 25.661 is provided.

[00148] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 10.0, 13.5, 16.9, 21.7, 24.9 and 25.7 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.98, 13.46, 16.921, 21.741, 24.899 and 25.661 is provided.

[00149] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.5, 10.0, 13.5, 16.9, 18.1, 19.8, 21.2, 21.7, 23.3, 24.9 and 25.7 is provided. In

a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.46, 9.98, 13.46, 16.921, 18.12, 19.842, 21.239, 21.741, 23.319, 24.899 and 25.661 is provided.

[00150] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile which has an XRPD diffraction pattern substantially the same as Figure 5 is provided.

[00151] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 5 is provided.

[00152] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile which is characterized by an endotherm at about 224.2°C is provided.

[00153] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile which is characterized by a DSC scan substantially the same as Figure 35 is provided.

[00154] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile comprising:

[00155] (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and ACN; and

[00156] (b) recrystallizing the solid to prepare Form B Acetonitrile.

[00157] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a).

[00158] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone is provided. In certain embodiments, a substantially pure

crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone is provided. Form B Acetone can be distinguished by the XRPD diffraction in Figure 6 and/or peak assignments of the XRPD diffraction of Figure 6 in Table 6.

[00159] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 9.9 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 9.936 is provided.

[00160] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.9, 17.0, 18.0, 24.7 and 25.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.936, 17.02, 17.98, 24.679 and 25.52 is provided.

[00161] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.4, 9.9, 13.0, 17.0, 18.0, 19.8, 23.5, 24.7 and 25.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.378, 9.936, 13.041, 17.02, 17.98, 19.758, 23.498, 24.679 and 25.52 is provided.

[00162] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone which has an XRPD diffraction pattern substantially the same as Figure 6 is provided.

[00163] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form B Acetone which is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) substantially the same as Table 6 is provided.

[00164] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone which is characterized by an endotherm at about 114.5°C and 224.1°C is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone which is characterized by an endotherm at about 224.1°C is provided.

[00165] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone which is characterized by a DSC scan substantially the same as Figure 36 is provided.

[00166] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone comprising:

[00167] (a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and acetone;

[00168] (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and acetone; and

[00169] (c) recrystallizing the solid to prepare Form B Acetone.

[00170] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

[00171] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane is provided. Form B Dichloromethane can be distinguished by the XRPD diffraction in Figure 7 and/or peak assignments of the XRPD diffraction of Figure 7 in Table 7.

[00172] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form B Dichloromethane, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.9 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.918 is provided.

[00173] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 10.0, 13.4, 16.9, 20.7 and 25.6 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.977, 13.381, 16.918, 20.738 and 25.641 is provided.

[00174] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.4, 10.0, 13.4, 16.9, 18.0, 20.7, 24.8 and 25.6 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.439, 9.977, 13.381, 16.918, 18.041, 20.738, 24.779 and 25.641 is provided.

[00175] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.4, 10.0, 13.4, 16.9, 17.4, 18.0, 18.3, 19.9, 20.7, 21.2, 21.8, 23.5, 24.8 and 25.6 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.439, 9.977, 13.381, 16.918, 17.438, 18.041, 18.34, 19.899, 20.738, 21.161, 21.802, 23.46, 24.779 and 25.641 is provided.

[00176] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form B Dichloromethane which has an XRPD diffraction pattern substantially the same as Figure 7 is provided.

[00177] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane which is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) substantially the same as Table 7 is provided.

[00178] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane which is characterized by an endotherm at about 129.1°C and 220.7°C is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane which is characterized by an endotherm at about 220.7°C is provided.

[00179] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane which is characterized by a DSC scan substantially the same as Figure 37 is provided.

[00180] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane comprising:

[00181] (a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DCM;

[00182] (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DCM; and

[00183] (c) recrystallizing the solid to prepare Form B Dichloromethane.

[00184] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

[00185] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran

is provided. Form B Tetrahydrofuran can be distinguished by the XRPD diffraction in Figure 8 and/or peak assignments of the XRPD diffraction of Figure 8 in Table 8.

[00186] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 25.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 25.44 is provided.

[00187] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.8, 16.7, 17.9, 24.7 and 25.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.819, 16.7, 17.92, 24.66 and 25.44 is provided.

[00188] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.8, 13.4, 16.7, 17.9, 21.4, 24.7 and 25.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.819, 13.38, 16.7, 17.92, 21.4, 24.66 and 25.44 is provided.

[00189] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.8, 13.4, 16.7, 17.9, 21.4, 22.9, 24.7 and 25.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.819, 13.38, 16.7, 17.92, 21.4, 22.92, 24.66 and 25.44 is provided.

[00190] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran which has an XRPD diffraction pattern substantially the same as Figure 8 is provided.

[00191] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 8 is provided.

[00192] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran which is characterized by an endotherm at about 228.5°C is provided.

[00193] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran which is characterized by a DSC scan substantially the same as Figure 38 is provided.

[00194] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran comprising:

[00195] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and THF; and

[00196] (b) recrystallizing the solid to prepare Form B Tetrahydrofuran.

[00197] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous is provided. Form B Anhydrous can be distinguished by the XRPD diffraction in Figure 9 and/or peak assignments of the XRPD diffraction of Figure 9 in Table 9.

[00198] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 9.9 is provided. In a further embodiment, a crystalline polymorph

*N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 9.938 is provided.

[00199] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.9, 13.6, 18.1, 21.5 and 25.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.938, 13.641, 18.1, 21.498 and 25.541 is provided.

[00200] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.4, 9.9, 13.6, 16.8, 17.1, 18.1, 21.2, 21.5, 24.9 and 25.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.44, 9.938, 13.641, 16.841, 17.099, 18.1, 21.22, 21.498, 24.901 and 25.541 is provided.

[00201] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous which has an XRPD diffraction pattern substantially the same as Figure 9 is provided.

[00202] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 9 is provided.

[00203] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous comprising:

[00204] (a) heating *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B; and

[00205] (b) recovering the solid to prepare Form B Anhydrous.

[00206] The Form B in Step (a) may be Form B Methanol, Ethanol, Isopropyl Alcohol, Acetonitrile, Acetone, Dichloromethane or Tetrahydrofuran. In certain embodiments, the Form B in Step (a) is Form B Ethanol. In certain embodiments, the heating in Step (a) is done at about 100 to about 200°C.

Form C

[00207] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C is provided. Form C can be distinguished by the XRPD diffraction in Figure 10 and/or peak assignments of the XRPD diffraction of Figure 10 in Table 10.

[00208] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C, characterized by at least one specific XRPD diffraction peak at about (2θ degrees ± 0.2) 5.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C, characterized by at least one specific XRPD diffraction peak at about (2θ degrees ± 0.2) 5.04 is provided.

[00209] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 5.0, 14.4, 15.3, 18.4 and 18.9 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 5.04, 14.435, 15.301, 18.437 and 18.902 is provided.

[00210] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 5.0, 7.2, 10.2, 14.4, 15.3, 15.7, 17.5, 18.4, 18.9, 19.6, 22.3 and 24.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 5.04, 7.159, 10.159, 14.435, 15.301, 15.717, 17.501, 18.437, 18.902, 19.638, 22.34 and 24.181 is provided.

[00211] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 5.0, 7.2, 10.2, 14.4, 15.3, 15.7, 16.7, 17.5, 18.1, 18.4, 18.9, 19.6, 21.1, 21.4, 22.3 and 24.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 5.04, 7.159, 10.159, 14.435, 15.301, 15.717, 16.719, 17.501, 18.059, 18.437, 18.902, 19.638, 21.08, 21.437, 22.34 and 24.181 is provided.

[00212] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C which has an XRPD diffraction pattern substantially the same as Figure 10 is provided.

[00213] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 10 is provided.

[00214] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C which is characterized by an endotherm at about 253.6°C is provided.

[00215] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C which is characterized by a DSC scan substantially the same as Figure 39 is provided.

[00216] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C comprising:

[00217] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and 2-methoxyethanol;

[00218] (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 2-methoxyethanol; and

[00219] (c) recrystallizing the solid to prepare Form C.

[00220] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a) to about 50°C.

Form D

[00221] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D is provided. Form D forms isomorphic solvates. Form D can be distinguished by the representative XRPD diffraction in Figures 11 to 14 and/or representative peak assignments of the XRPD diffraction of Figures 11 to 14 in Tables 11 to 14.

[00222] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.3) 8.0 and 12.7 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.0 and 12.7 is provided.

[00223] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.3) 8.0 and 12.6 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.0 and 12.6 is provided.

[00224] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.4) 8.0, 9.8, 11.3, 12.7, 13.9, 16.1, 17.1 and 19.8 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.0, 9.8, 11.3, 12.7, 13.9 and 17.1 is provided.

[00225] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.3) 8.0, 9.8, 11.3, 12.6, 13.9, 16.2, 17.2 and 19.7 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.0, 9.8, 11.3, 12.6, 13.9, 17.2 and 19.7 is provided.

[00226] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.5) 8.0, 9.8, 11.3, 12.7, 13.9, 16.1, 17.1, 19.8, 21.4, 22.1, 23.6, 25.3 and 27.5 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.0, 9.8, 11.3, 12.7, 13.9, 17.2, 22.1 and 25.3 is provided.

[00227] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.3) 8.0, 9.8, 11.3, 12.6, 13.9, 16.2, 17.2, 19.7, 21.3, 22.1, 23.4, 25.3 and 27.4 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.0, 9.8, 11.3, 12.6, 13.9, 17.2, 19.7, 22.1 and 25.3 is provided.

[00228] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D comprising:

[00229] (a1) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from EtOAc, dioxane and propyl acetate, or

[00230] (a2) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and a solvent selected from acetone and propyl acetate, and

[00231] (b) recrystallizing the solid to prepare Form D.

[00232] In certain embodiments, the solvent in Step (a1) is selected from EtOAc and dioxane.

[00233] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate is provided. Form D Ethyl Acetate can be distinguished by the XRPD diffraction in Figure 11 and/or peak assignments of the XRPD diffraction of Figure 11 in Table 11.

[00234] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 8.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 7.959 is provided.

[00235] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.0, 12.7, 16.1, 17.1 and 19.8 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.959, 12.66, 16.099, 17.118 and 19.761 is provided.

[00236] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.0, 9.8, 11.3, 12.7, 16.1, 17.1, 19.8 and 23.6 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.959, 9.798, 11.321, 12.66, 16.099, 17.118, 19.761 and 23.599 is provided.

[00237] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form D Ethyl Acetate which has an XRPD diffraction pattern substantially the same as Figure 11 is provided.

[00238] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate which is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) substantially the same as Table 11 is provided.

[00239] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate which is characterized by endotherms at about 113.0°C and 240.3°C is provided.

[00240] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate which is characterized by a DSC scan substantially the same as Figure 40 is provided.

[00241] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate comprising:

[00242] (a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and EtOAc; and

[00243] (b) recrystallizing the solid to prepare Form D Ethyl Acetate.

[00244] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane is provided. Form D Dioxane can be distinguished by the XRPD diffraction in Figure 12 and/or peak assignments of the XRPD diffraction of Figure 12 in Table 12.

[00245] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane, characterized by at least one specific XRPD diffraction peak at about (2θ degrees ± 0.2) 19.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-

dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane, characterized by at least one specific XRPD diffraction peak at about (2θ degrees ± 0.2) 19.54 is provided.

[00246] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.8, 11.1, 12.5, 19.5 and 23.1 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.822, 11.139, 12.5, 19.54 and 23.139 is provided.

[00247] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.8, 11.1, 12.5, 19.5, 21.1, 23.1, 24.0 and 27.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.822, 11.139, 12.5, 19.54, 21.062, 23.139, 24.022 and 27.179 is provided.

[00248] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.8, 11.1, 12.5, 17.1, 17.7, 19.5, 21.1, 23.1, 24.0 and 27.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.822, 11.139, 12.5, 17.135, 17.703, 19.54, 21.062, 23.139, 24.022 and 27.179 is provided.

[00249] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane which has an XRPD diffraction pattern substantially the same as Figure 12 is provided.

[00250] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane which is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) substantially the same as Table 12 is provided.

[00251] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane which is characterized by endotherms at about 109.8°C, 238.2°C and 250.2°C and an exotherm at about 170.8°C is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane which is characterized by endotherms at about 109.8°C, 238.2°C and 250.2°C is provided.

[00252] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane which is characterized by a DSC scan substantially the same as Figure 41 is provided.

[00253] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane comprising:

[00254] (a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and dioxane; and

[00255] (b) recrystallizing the solid to prepare Form D Dioxane.

[00256] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone is provided. Form D Acetone can be distinguished by the XRPD diffraction in Figure 13 and/or peak assignments of the XRPD diffraction of Figure 13 in Table 13.

[00257] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 8.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 7.999 is provided.

[00258] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form D Acetone, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.0, 17.1, 21.4, 23.6 and 27.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.999, 17.14, 21.378, 23.561 and 27.482 is provided.

[00259] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.0, 13.9, 16.1, 17.1, 19.8, 21.4, 23.6 and 27.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.999, 13.923, 16.101, 17.14, 19.761, 21.378, 23.561 and 27.482 is provided.

[00260] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.0, 9.9, 12.7, 13.9, 16.1, 17.1, 18.0, 19.8, 21.4, 22.1, 23.6, 24.3 and 27.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.999, 9.856, 12.681, 13.923, 16.101, 17.14, 18, 19.761, 21.378, 22.103, 23.561, 24.259 and 27.482 is provided.

[00261] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone which has an XRPD diffraction pattern substantially the same as Figure 13 is provided.

[00262] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone which is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) substantially the same as Table 13 is provided.

[00263] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form D Acetone which is characterized by endotherms at about 108.5°C and 235.1°C is provided.

[00264] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone which is characterized by a DSC scan substantially the same as Figure 42 is provided.

[00265] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone comprising:

[00266] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and acetone; and

[00267] (b) recrystallizing the solid to prepare Form D Acetone.

[00268] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate is provided. Form D Propyl Acetate can be distinguished by the XRPD diffraction in Figure 14 and/or peak assignments of the XRPD diffraction of Figure 14 in Table 14.

[00269] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate, characterized by at least one specific XRPD diffraction peak at about (2θ degrees ± 0.2) 8.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate, characterized by at least one specific XRPD diffraction peak at about (2θ degrees ± 0.2) 7.999 is provided.

[00270] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 8.0, 12.7, 16.1, 17.1 and 19.8 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2) 7.99, 12.719, 16.121, 17.16 and 19.782 is provided.

[00271] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.0, 12.7, 16.1, 17.1, 19.8, 23.6 and 27.6 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.99, 12.719, 16.121, 17.16, 19.782, 23.62 and 27.579 is provided.

[00272] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.0, 9.8, 12.7, 13.9, 16.1, 17.1, 18.0, 19.8, 21.4, 23.6, 24.3 and 27.6 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.99, 9.839, 12.719, 13.903, 16.121, 17.16, 18.021, 19.782, 21.42, 23.62, 24.28 and 27.579 is provided.

[00273] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate which has an XRPD diffraction pattern substantially the same as Figure 14 is provided.

[00274] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 14 is provided.

[00275] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate which is characterized by endotherms at about 119.6°C and 247.7°C is provided.

[00276] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate which is characterized by a DSC scan substantially the same as Figure 43 is provided.

[00277] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate comprising:

[00278] (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and propyl acetate; and

[00279] (b) recrystallizing the solid to prepare Form D Propyl Acetate.

[00280] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a).

Form E

[00281] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is provided. Form E can be distinguished by the XRPD diffraction in Figure 15 and/or peak assignments of the XRPD diffraction of Figure 15 in Table 15.

[00282] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.1 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.06 is provided.

[00283] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.7, 9.4, 11.9, 16.1 and 23.7 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.659, 9.353, 11.904, 16.06 and 23.739 is provided.

[00284] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E which has an XRPD diffraction pattern substantially the same as Figure 15 is provided.

[00285] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 15 is provided.

[00286] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E which is characterized by endotherms at about 149.7°C and 253.1°C is provided.

[00287] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E which is characterized by a DSC scan substantially the same as Figure 44 is provided.

[00288] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E comprising:

[00289] (a) mixing 1-(4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea in THF under basic conditions;

[00290] (b) adding water to the mixture to form an oil of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine;

[00291] (c) recovering the product as *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E.

[00292] In certain embodiments, the basic conditions in Step (a) are provided by 2.5N NaOH.

Form F

[00293] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F is provided. In certain embodiments, a substantially pure crystalline

polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F is provided. Form F can be distinguished by the XRPD diffraction in Figure 16 and/or peak assignments of the XRPD diffraction of Figure 16 in Table 16.

[00294] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.6 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.56 is provided.

[00295] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 14.9, 16.6, 16.9, 19.1 and 21.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 14.899, 16.56, 16.92, 19.098 and 21.18 is provided.

[00296] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 14.9, 16.6, 16.9, 19.1, 21.2 and 22.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 14.899, 16.56, 16.92, 19.098, 21.18 and 22.537 is provided.

[00297] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F which has an XRPD diffraction pattern substantially the same as Figure 16 is provided.

[00298] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 16 is provided.

[00299] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F which is characterized by endotherms at about 122.7°C, 234.2°C and 250.5°C is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F which is characterized by endotherms at about 122.7°C and 250.5°C is provided.

[00300] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F which is characterized by a DSC scan substantially the same as Figure 45 is provided.

[00301] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F comprising:

[00302] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and ethyl acetate; and

[00303] (b) recrystallizing the solid to prepare Form F.

Form G

[00304] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G is provided. Form G forms isomorphic solvates. Form G can be distinguished by the representative XRPD diffraction in Figures 17 to 20 and/or representative peak assignments of the XRPD diffraction of Figures 17 to 20 in Tables 17 to 20.

[00305] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.4) 7.8 and 23.1 is provided.

[00306] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.3)

7.8 and 23.2 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 7.8 is provided.

[00307] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.4) 7.8, 11.1 and 23.1 is provided.

[00308] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.3) 7.8, 11.2 and 23.2 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8 and 11.2 is provided.

[00309] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.5) 7.8, 8.2, 9.4, 11.1, 16.6, 23.1, 24.1 and 27.8 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8, 8.2, 9.4 and 16.6 is provided.

[00310] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.3) 7.8, 8.1, 9.3, 11.2, 16.6, 23.2, 24.3 and 27.6 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8, 8.1, 9.3, 11.2 and 16.6 is provided.

[00311] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.5) 5.6, 7.8, 8.2, 9.4, 11.1, 12.7, 15.6, 16.6, 20.0, 21.0, 23.1, 23.4, 24.1 and 27.8 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-

3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 5.6, 7.8, 8.2, 9.4, 12.7 and 16.6 is provided.

[00312] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.3) 5.6, 7.8, 8.1, 9.3, 11.2, 12.7, 15.7, 16.6, 20.0, 21.2, 23.2, 23.5, 24.3 and 27.6 is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 5.6, 7.8, 8.1, 9.3, 11.2, 12.7, 16.6 and 21.2 is provided.

[00313] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G comprising:

[00314] (a1) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and 20:80 THF:water, or

[00315] (a2) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from isopropyl acetate and MIBK, and

[00316] (b) recrystallizing the solid to prepare Form G; or

[00317] (c) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and tetrahydrofuran,

[00318] (d) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF, and

[00319] (e) recrystallizing the solid to prepare Form G.

[00320] In certain embodiments, the solution in Step (d) is created by heating the mixture of Step (c) to reflux.

[00321] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a2).

[00322] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran is provided. Form G hemi-Tetrahydrofuran can be distinguished by the XRPD diffraction in Figure 17 and/or peak assignments of the XRPD diffraction of Figure 17 in Table 17.

[00323] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 23.1 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 23.079 is provided.

[00324] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.7, 11.1, 12.3, 23.1 and 24.1 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.719, 11.102, 12.281, 23.079 and 24.099 is provided.

[00325] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.7, 11.1, 12.3, 23.1, 24.1 and 27.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G

hemi-Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.719, 11.102, 12.281, 23.079, 24.099 and 27.503 is provided.

[00326] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran which has an XRPD diffraction pattern substantially the same as Figure 17 is provided.

[00327] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 17 is provided.

[00328] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran which is characterized by endotherms at about 106.1°C and 232.3°C is provided.

[00329] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran which is characterized by a DSC scan substantially the same as Figure 46 is provided.

[00330] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran comprising:

[00331] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and 20:80 THF:water; and

[00332] (b) recrystallizing the solid to prepare Form G hemi-Tetrahydrofuran.

[00333] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran is provided. Form G mono-Tetrahydrofuran can be distinguished by the XRPD diffraction in Figure 18 and/or peak assignments of the XRPD diffraction of Figure 18 in Table 18.

[00334] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 23.1 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 23.022 is provided.

[00335] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.7, 11.1, 12.4, 23.0 and 24.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.72, 11.137, 12.401, 23.022 and 24.042 is provided.

[00336] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.7, 8.0, 9.4, 11.1, 12.4, 16.6, 21.0, 23.0, 23.4, 24.0 and 27.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.72, 8.003, 9.417, 11.137, 12.401, 16.599, 21.017, 23.022, 23.397, 24.042 and 27.482 is provided.

[00337] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran which has an XRPD diffraction pattern substantially the same as Figure 18 is provided.

[00338] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 18 is provided.

[00339] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran which is characterized by endotherms at about 113.2°C and 232.3°C is provided.

[00340] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran which is characterized by a DSC scan substantially the same as Figure 47 is provided.

[00341] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran comprising:

[00342] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and tetrahydrofuran;

[00343] (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF; and

[00344] (c) recrystallizing the solid to prepare Form G mono-Tetrahydrofuran.

[00345] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

[00346] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate is provided. Form G Isopropyl Acetate can be distinguished by the XRPD diffraction in Figure 19 and/or peak assignments of the XRPD diffraction of Figure 19 in Table 19.

[00347] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 23.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate,

characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 23.438 is provided.

[00348] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8, 8.3, 11.4, 13.2 and 23.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.803, 8.299, 11.398, 13.18 and 23.438 is provided.

[00349] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8, 8.3, 9.4, 11.4, 13.2, 16.6, 23.4 and 24.4 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.803, 8.299, 9.361, 11.398, 13.18, 16.64, 23.438 and 24.381 is provided.

[00350] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8, 8.3, 9.4, 11.4, 12.7, 13.2, 16.6, 18.1, 19.6, 20.0, 21.7, 23.4, 24.4 and 27.8 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.803, 8.299, 9.361, 11.398, 12.7, 13.18, 16.64, 18.099, 19.639, 19.979, 21.738, 23.438, 24.381 and 27.821 is provided.

[00351] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate which has an XRPD diffraction pattern substantially the same as Figure 19 is provided.

[00352] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form G Isopropyl Acetate which is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) substantially the same as Table 19 is provided.

[00353] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate which is characterized by endotherms at about 123.3°C, 221.3°C and 237.0°C is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate which is characterized by endotherms at about 123.3°C and 237.0°C is provided.

[00354] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate which is characterized by a DSC scan substantially the same as Figure 48 is provided.

[00355] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate comprising:

[00356] (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and isopropyl acetate; and

[00357] (b) recrystallizing the solid to prepare Form G Isopropyl Acetate.

[00358] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a).

[00359] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone is provided. Form G Methyl Isobutyl Ketone can be distinguished by the XRPD diffraction in Figure 20 and/or peak assignments of the XRPD diffraction of Figure 20 in Table 20.

[00360] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form G Methyl Isobutyl Ketone, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 23.3 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 23.28 is provided.

[00361] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8, 8.2, 11.2, 16.5 and 23.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.78, 8.217, 11.239, 16.503 and 23.28 is provided.

[00362] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8, 8.2, 9.3, 11.2, 13.1, 16.5, 19.9, 21.4, 23.2, 24.6 and 27.8 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.78, 8.217, 9.298, 11.239, 13.079, 16.503, 19.858, 21.442, 23.28, 24.562 and 27.759 is provided.

[00363] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.8, 8.2, 9.3, 11.2, 12.3, 12.6, 13.1, 16.5, 19.9, 21.4, 23.2, 23.6, 24.6 and 27.8 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.78, 8.217, 9.298, 11.239, 12.341, 12.575, 13.079, 16.503, 19.858, 21.442, 23.28, 23.619, 24.562 and 27.759 is provided.

[00364] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form G Methyl Isobutyl Ketone which has an XRPD diffraction pattern substantially the same as Figure 20 is provided.

[00365] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 20 is provided.

[00366] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone which is characterized by endotherms at about 102.2°C, 234.8°C and 251.4°C is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone which is characterized by endotherms at about 234.8°C and 251.4°C is provided.

[00367] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone which is characterized by a DSC scan substantially the same as Figure 49 is provided.

[00368] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone comprising:

[00369] (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MIBK; and

[00370] (b) recrystallizing the solid to prepare Form G Methyl Isobutyl Ketone.

[00371] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a).

Form H

[00372] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H is provided. Form H can be

distinguished by the XRPD diffraction in Figure 21 and/or peak assignments of the XRPD diffraction of Figure 21 in Table 21.

[00373] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 11.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 11.18 is provided.

[00374] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 11.2, 16.1, 19.6, 22.0 and 25.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 11.18, 16.08, 19.58, 22.04 and 25.501 is provided.

[00375] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H which has an XRPD diffraction pattern substantially the same as Figure 21 is provided.

[00376] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 21 is provided.

[00377] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H which is characterized by an endotherm at about 231.6°C is provided.

[00378] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H which is characterized by a DSC scan substantially the same as Figure 50 is provided.

[00379] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H comprising:

[00380] (a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MTBE; and

[00381] (b) recrystallizing the solid to prepare Form H.

Form I

[00382] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I is provided. Form I can be distinguished by the XRPD diffraction in Figure 22 and/or peak assignments of the XRPD diffraction of Figure 22 in Table 22.

[00383] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 7.2 is provided.

[00384] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.2, 16.6, 18.3, 22.3 and 23.1 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.2, 16.559, 18.303, 22.282 and 23.101 is provided.

[00385] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.2, 12.1, 16.3, 16.6, 18.3, 19.3, 19.5, 20.6, 22.3 and 23.1 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 7.2, 12.117, 16.319, 16.559, 18.303, 19.32, 19.54, 20.641, 22.282 and 23.101 is provided.

[00386] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form I which has an XRPD diffraction pattern substantially the same as Figure 22 is provided.

[00387] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 22 is provided.

[00388] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I which is characterized by endotherms at about 132.6°C and 236.3°C and an exotherm at about 183.3°C is provided.

[00389] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I which is characterized by a DSC scan substantially the same as Figure 51 is provided.

[00390] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I comprising:

[00391] (a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and xylene; and

[00392] (b) recrystallizing the solid to prepare Form I.

Form J

[00393] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J is provided. Form J can be distinguished by the XRPD diffraction in Figure 23 and/or peak assignments of the XRPD diffraction of Figure 23 in Table 23.

[00394] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 17.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-

dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.963 is provided.

[00395] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 4.5, 9.0, 17.0, 18.0 and 18.8 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 4.479, 8.982, 16.963, 18.078 and 18.797 is provided.

[00396] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J which has an XRPD diffraction pattern substantially the same as Figure 23 is provided.

[00397] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 23 is provided.

[00398] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J comprising:

[00399] (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 2-methoxyethanol; and

[00400] (b) recrystallizing the solid to prepare Form J.

[00401] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a).

Form K

[00402] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K is provided. Form K can be

distinguished by the XRPD diffraction in Figure 24 and/or peak assignments of the XRPD diffraction of Figure 24 in Table 24.

[00403] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 22.8 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 22.78 is provided.

[00404] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 15.8, 17.6, 22.8, 23.0 and 25.7 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 15.797, 17.62, 22.78, 23 and 25.701 is provided.

[00405] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 13.9, 15.8, 17.6, 19.0, 22.8, 23.0 and 25.7 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 13.923, 15.797, 17.62, 18.999, 22.78, 23 and 25.701 is provided.

[00406] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K which has an XRPD diffraction pattern substantially the same as Figure 24 is provided.

[00407] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 24 is provided.

[00408] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form K which is characterized by endotherms at about 119.3°C, 241.2°C and 253.4°C and an exotherm at about 171.6°C is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K which is characterized by endotherms at about 241.2°C and 253.4°C and an exotherm at about 171.6°C is provided.

[00409] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K which is characterized by a DSC scan substantially the same as Figure 52 is provided.

[00410] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K comprising:

[00411] (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DME; and

[00412] (b) recrystallizing the solid to prepare Form K.

[00413] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a).

Form L

[00414] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L is provided. Form L can be distinguished by the XRPD diffraction in Figure 25 and/or peak assignments of the XRPD diffraction of Figure 25 in Table 25.

[00415] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L, characterized by at least one specific XRPD diffraction peak at about (2θ degrees ± 0.2) 17.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-

dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 16.98 is provided.

[00416] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 14.9, 17.0, 19.0, 21.1 and 22.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 14.899, 16.98, 18.958, 21.062 and 22.457 is provided.

[00417] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L which has an XRPD diffraction pattern substantially the same as Figure 25 is provided.

[00418] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 25 is provided.

[00419] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L which is characterized by endotherms at about 120.4°C and 251.6°C and an exotherm at about 202.3°C is provided.

[00420] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L which is characterized by a DSC scan substantially the same as Figure 53 is provided.

[00421] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L comprising:

[00422] (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MeOAc; and

[00423] (b) recrystallizing the solid to prepare Form L.

[00424] In certain embodiments, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E is used in Step (a).

Form M

[00425] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M is provided. Form M can be distinguished by the XRPD diffraction in Figure 26 and/or peak assignments of the XRPD diffraction of Figure 26 in Table 26.

[00426] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 9.0 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 8.982 is provided.

[00427] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.0, 15.1, 20.7, 23.1 and 26.8 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 8.982, 15.136, 20.738, 23.083 and 26.76 is provided.

[00428] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M which has an XRPD diffraction pattern substantially the same as Figure 26 is provided.

[00429] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 26 is provided.

[00430] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M which is characterized by endotherms at about 124.2°C, 229.0°C, 246.0°C and 256.0°C and an exotherm at about 198.4°C is provided. In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M which is characterized by endotherms at about 124.2°C and 246.0°C and an exotherm at about 198.4°C is provided.

[00431] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M which is characterized by a DSC scan substantially the same as Figure 54 is provided.

[00432] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M comprising:

[00433] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol and 1:1 THF:water; and

[00434] (b) recrystallizing the solid to prepare Form M.

Form N

[00435] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N is provided. Form N can be distinguished by the XRPD diffraction in Figure 27 and/or peak assignments of the XRPD diffraction of Figure 27 in Table 27.

[00436] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 22.9 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 22.92 is provided.

[00437] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 15.9, 17.8, 19.2, 22.9 and 25.9 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 15.88, 17.759, 19.202, 22.92 and 25.881 is provided.

[00438] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 14.0, 15.9, 17.8, 18.1, 19.2, 22.9 and 25.9 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 14.02, 15.88, 17.759, 18.08, 19.202, 22.92 and 25.881 is provided.

[00439] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N which has an XRPD diffraction pattern substantially the same as Figure 27 is provided.

[00440] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 27 is provided.

[00441] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N which is characterized by endotherms at about 111.0°C and 242.4°C and an exotherm at about 146.1°C is provided.

[00442] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N which is characterized by a DSC scan substantially the same as Figure 55 is provided.

[00443] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N comprising:

- [00444] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol and a solution of 1% sodium carboxymethyl cellulose, 0.1% Tween® in water; and
- [00445] (b) recrystallizing the solid to prepare Form N.

Form O

[00446] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O is provided. Form O can be distinguished by the XRPD diffraction in Figure 28 and/or peak assignments of the XRPD diffraction of Figure 28 in Table 28.

[00447] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 11.2 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O, characterized by at least one specific XRPD diffraction peak at about (2θ degrees $\pm$ 0.2) 11.238 is provided.

[00448] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 11.2, 16.5, 20.0, 22.2 and 25.6 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 11.238, 16.52, 19.98, 22.179 and 25.638 is provided.

[00449] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O which has an XRPD diffraction pattern substantially the same as Figure 28 is provided.

[00450] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 28 is provided.

[00451] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O which is characterized by an endotherm at about 245.4°C is provided.

[00452] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O which is characterized by a DSC scan substantially the same as Figure 56 is provided.

[00453] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O comprising:

[00454] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran with THF;

[00455] (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF; and

[00456] (c) recrystallizing the solid to prepare Form O.

[00457] In certain embodiments, the solution in Step (b) is created by heating the mixture of Step (a) to about 50°C.

Form P

[00458] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P is provided. In certain embodiments, a substantially pure crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P is provided. Form P can be distinguished by the XRPD diffraction in Figure 29 and/or peak assignments of the XRPD diffraction of Figure 29 in Table 29.

[00459] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P, characterized by at least one specific XRPD diffraction peak at about (2θ degrees ± 0.2) 23.5 is provided.

[00460] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P, characterized by XRPD diffraction peaks at about (2θ degrees ± 0.2)

9.9, 13.7, 15.7, 17.7 and 23.5 is provided. In a further embodiment, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P, characterized by XRPD diffraction peaks at about (2θ degrees $\pm$ 0.2) 9.901, 13.74, 15.662, 17.661 and 23.5 is provided.

[00461] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P which has an XRPD diffraction pattern substantially the same as Figure 29 is provided.

[00462] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P which is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) substantially the same as Table 29 is provided.

[00463] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P which is characterized by endotherms at about 159.2°C, 246.7°C and 262.2°C is provided.

[00464] In certain embodiments, a crystalline polymorph *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P which is characterized by a DSC scan substantially the same as Figure 57 is provided.

[00465] Certain embodiments provide a process for preparing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P comprising:

[00466] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Tetrahydrofuran with water; and

[00467] (b) recrystallizing the solid to prepare Form P.

Amorphous

[00468] In certain embodiments, amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is provided. In certain embodiments, substantially pure amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is provided. Amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-

methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is identified in the XRPD of Figure 30.

[00469] In certain embodiments, amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine which has an XRPD diffraction pattern substantially the same as Figure 30 is provided.

[00470] In certain embodiments, amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine which is characterized by an mDSC scan substantially the same as Figure 58 is provided.

[00471] Certain embodiments provide a process for preparing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine comprising:

[00472] (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol with 3:7 water:THF;

[00473] (b) sonicating the solution of Step (a);

[00474] (c) freezing and lyophilizing the solution to prepare amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.

[00475] The invention also includes isotopically-labeled *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, which is identical, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen and oxygen, such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O and ^{17}O , respectively. The polymorphs described herein, which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes, such as ^3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, *i.e.*, ^3H and carbon-14, *i.e.*, ^{14}C , isotopes are particularly widely used as a result of their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, *i.e.*, ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be utilized in some particular circumstances. Isotopically labeled salts of the present invention can generally be prepared by carrying out

procedures disclosed in WO 03/077914 by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent during the preparation, or if desired, using an isotopically labeled sulfuric acid in the preparation of the salt.

SYNTHESIS OF COMPOUNDS

[00476] Compounds described herein may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources such as Sigma-Aldrich (St. Louis, MO), Alfa Aesar (Ward Hill, MA), or TCI (Portland, OR), or are readily prepared using methods well known to those skilled in the art (*e.g.*, prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-23, New York: Wiley 1967-2006 ed. (also available via the Wiley InterScience® website), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).

[00477] The synthesis of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is described in WO 2007/059257. Generally, *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine may be prepared by coupling (*E*)-*N'*-(2-cyano-4-(3-(1-hydroxy-2-methylpropan-2-yl)thioureido)phenyl)-*N,N*-dimethylformimidamide with 4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylaniline in isopropyl acetate:acetic acid (65:35 v/v) at 45°C to yield 1-(4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea. The 1-(4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea may then be agitated in tetrahydrofuran under basic conditions (2.5N NaOH), followed by the addition of *p*-toluenesulfonyl chloride. Water may then be charged to yield *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine as a mixture of polymorphs (generally a mixture containing one or more of Form C, Form G hemi-THF, Form G mono-THF, Form M or Form P). The final crystallizations or isolations will determine the polymorphic form, which are further detailed in the Examples section.

[00478] For a more detailed description of the individual reaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds.

ADMINISTRATION AND PHARMACEUTICAL FORMULATIONS

[00479] The compounds described herein may be administered by any convenient route appropriate to the condition to be treated. Suitable routes include oral, parenteral (including subcutaneous, intramuscular, intravenous, intraarterial, intradermal, intrathecal and epidural), transdermal, rectal, nasal, topical (including buccal and sublingual), ocular, vaginal, intraperitoneal, intrapulmonary and intranasal.

[00480] The compounds may be administered in any convenient administrative form, *e.g.*, tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, *e.g.*, diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. If parenteral administration is desired, the compositions will be sterile and in a solution or suspension form suitable for injection or infusion.

[00481] A typical formulation is prepared by mixing a compound described herein and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, *e.g.*, Ansel, Howard C., *et al.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., *et al.* Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (*i.e.*, a compound described herein or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (*i.e.*, medicament).

[00482] One embodiment includes a pharmaceutical composition comprising a polymorph or amorphous compound described herein. A further embodiment provides a pharmaceutical composition comprising a polymorph or amorphous compound described herein, together with a pharmaceutically acceptable carrier or excipient.

[00483] The amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.01 to about 100 mg per kg body weight per day,

preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.7 to 7000 mg/day, preferably about 70 to about 2500 mg/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day. A unit dosage form such as a tablet or capsule will usually contain, for example 1-1000 mg of active ingredient, and preferably 5-420 mg of active ingredient. Preferably a daily dose in the range of 0.03-6 mg/kg is employed.

METHODS OF TREATMENT WITH COMPOUNDS OF THE INVENTION

[00484] Also provided are methods of treating or preventing disease or condition by administering the pharmaceutical compositions described herein. In one embodiment, a human patient is treated with a pharmaceutical composition described herein in an amount to detectably inhibit ErbB2 activity.

[00485] In another embodiment, a method of treating a hyperproliferative disease in a mammal comprising administering a pharmaceutical composition described herein, to the mammal is provided.

[00486] In another embodiment, a method of treating or preventing cancer in a mammal in need of such treatment, wherein the method comprises administering to said mammal a pharmaceutical composition described herein. The cancer is selected from breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, NSCLC, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, Hodgkin's and leukemia. Another embodiment provides the use of a pharmaceutical composition described herein, in the manufacture of a medicament for the treatment of cancer.

[00487] In another embodiment, the cancer is ErbB2 positive.

[00488] In another embodiment, the cancer is selected from breast, gastric, biliary, colorectal, brain, lung, NSCLC, pancreatic, head and neck, ovarian and uterine cancer.

[00489] In another embodiment, the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian and uterine cancer.

- [00490] In another embodiment, the cancer is selected from breast, gastric, colorectal, lung and ovarian cancer.
- [00491] In another embodiment, the cancer is selected from breast, ovarian, gastric and uterine cancer.
- [00492] In another embodiment, the cancer is selected from breast, gastric, colorectal, NSCLC and ovarian cancer.
- [00493] In another embodiment, the cancer is selected from breast, lung, pancreatic, colorectal and head and neck cancers.
- [00494] In another embodiment, the cancer is breast cancer.
- [00495] In another embodiment, the cancer is gastric cancer.
- [00496] In another embodiment, the cancer is biliary cancer.
- [00497] In another embodiment, the cancer is colorectal.
- [00498] In another embodiment, the cancer is lung cancer.
- [00499] In another embodiment, the cancer is NSCLC.
- [00500] In another embodiment, the cancer is pancreatic cancer.
- [00501] In another embodiment, the cancer is head and neck cancer.
- [00502] In another embodiment, the cancer is ovarian cancer.
- [00503] In another embodiment, the cancer is uterine cancer.
- [00504] In another embodiment, the cancer is brain cancer.
- [00505] In another embodiment, a method of treating or preventing a disease or disorder modulated by ErbB2, comprising administering to a mammal in need of such treatment an effective amount of a pharmaceutical composition described herein. Examples of such diseases and disorders include, but are not limited to, cancer.
- [00506] Another embodiment provides a compound described herein in the treatment of disease. In a further embodiment, the disease is a hyperproliferative disease. In a further embodiment, the hyperproliferative disease is cancer.
- [00507] Another embodiment provides the use of a pharmaceutical composition described herein, in the manufacture of a medicament for the treatment of cancer.

COMBINATION THERAPY

[00508] The polymorphs and pharmaceutical compositions described herein may be employed alone or in combination with other therapeutic agents for treatment. The compounds described herein may be used in combination with one or more additional drugs, for example an anti-hyperproliferative (or anti-cancer) agent that works through action on a different target protein. The second compound of the pharmaceutical combination

formulation or dosing regimen preferably has complementary activities to the compound described herein, such that they do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. The compounds may be administered together in a unitary pharmaceutical composition or separately and, when administered separately this may occur simultaneously or sequentially in any order. Such sequential administration may be close in time or remote in time.

EXAMPLES

[00509] For illustrative purposes, the following Examples are included. However, it is to be understood that these Examples do not limit the invention and are only meant to suggest a method of practicing the invention. Persons skilled in the art will recognize that the chemical reactions described may be readily adapted to prepare the compounds or polymorphs described herein, and alternative methods for preparing the compounds or polymorphs are deemed to be within the scope of this invention. For example, the synthesis of the compounds or polymorphs may be successfully performed by modifications apparent to those skilled in the art, *e.g.*, by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing the compounds or polymorphs described herein. Persons skilled in the art will also recognize that the polymorphs and compositions described may be readily adapted to prepare other polymorphs and compositions, and alternative methods for preparing the polymorphs and compositions, as well as alternative compositions are deemed to be within the scope of this invention.

[00510] In the Examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Sigma-Aldrich, Alfa Aesar, or TCI, and were used without further purification unless otherwise indicated. The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.

[00511] The XRPD analysis was conducted using a Rigaku X-Ray powder diffractometer (model Ultima III) operating with a Cu radiation source at 40 kW, 40 mA. Round standard aluminum sample holders with round zero background, and/or quartz plates were used for sample preparation. The scanning parameters were from a range of about 3-40

degree 2θ (± 0.2 degrees) and a continuous scan at a rate of about 2 degrees 2θ /minute. 2θ calibration was performed using a Si standard.

[00512] Peak assignment analysis was performed using Materials Data Inc. Jade 7 (Version V5.1.2600) program, which uses a peak search algorithm that is based on the Savitzky-Golay 2nd derivatives combined with the counting statistics of intensity data. The peak search on each crystal form was performed using the following parameters: Parabolic Filter, Peak Threshold = 3.0, Intensity Cutoff = 0.1%, Background = 3/1.0 and Peak Location = Summit. The Tables below include the analysis and are provided with the following approximate data: 2θ measured in degrees ± 0.2 degrees; d measured in angstroms ± 0.2 angstroms; and relative intensity using peak height to measure height % (H%) in counts per second.

[00513] Thermal transition values were measured by differential scanning calorimetry ("DSC") using a TA Instruments Q1000 DSC on approximately 2-10 mg samples in hermetically sealed aluminum pans with a pin-hole in the lid under an inert nitrogen atmosphere. A heating rate of $10^\circ\text{C}/\text{min}$ was used over the 25 - 275°C temperature range, and a second, empty aluminum pan was used as a reference.

[00514] Glass transition values were measured by modulated differential scanning calorimetry ("mDSC") using a TA Instruments Q1000 DSC on approximately 2-10 mg samples in hermetically sealed aluminum pans with a pin-hole in the lid under an inert nitrogen atmosphere. A heating rate of $2^\circ\text{C}/\text{min}$ with a modulation amplitude of $\pm 1.3^\circ\text{C}$ over a period of 60 seconds was used. Samples were analyzed over a 25 - 150°C temperature range, and a second, empty aluminum pan was used as a reference.

Example 1

*N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A*

[00515] Amorphous *N4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine* (20 mg) was added to a vial containing 1:1 EtOH:water (0.5 mL) and stirred for 48 hours at 50°C . The solution was cooled and filtered to yield Form A (Hydrate).

[00516] The XRPD scan is shown in Figure 1 and the peak assignments are in Table 1:

TABLE 1

2 θ	d (Å)	Relative Intensity
6.86	12.8745	34.5
9.158	9.6484	13.3
9.442	9.3588	18.5
9.723	9.0893	23.1
10.623	8.3213	29.6
10.943	8.0784	21.9
11.416	7.7451	13
12.78	6.921	49.4
13.637	6.4881	35.1
14.959	5.9175	6.7
15.219	5.8169	27.4
16.3	5.4336	48.8
16.94	5.2296	66.1
17.464	5.074	27.1
17.92	4.946	11.9
18.139	4.8867	12.3
18.339	4.8338	13.7
18.745	4.73	7.8
19.138	4.6337	87.5
19.44	4.5624	36.3
20.278	4.3758	100
20.885	4.2499	22
21.16	4.1952	51.3
21.863	4.062	69.2
22.098	4.0194	16.5

22.604	3.9305	8.2
23.139	3.8408	78.8
23.98	3.708	32.7
24.519	3.6276	44.2
25.202	3.5308	72.1
25.901	3.4371	24.4
26.181	3.401	20.2
26.86	3.3166	13.2
27.298	3.2643	31.9
27.733	3.2141	15.6
28.305	3.1504	7.4
28.864	3.0907	7.7
29.339	3.0417	16.6
29.66	3.0095	5.6
30.237	2.9534	5.3
30.642	2.9153	6.1
31.22	2.8626	11.9
32.042	2.791	5.7
32.459	2.7561	6.1
33.061	2.7073	15.9
33.318	2.687	4
33.802	2.6496	4.4
34.46	2.6005	8.9
35.679	2.5144	5.4
37.223	2.4136	3.8
38.178	2.3554	3.5
38.49	2.337	3.9

Example 2

N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Methanol Isomorph Solvate

[00517] N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (666.5 mg) was added to a 20 mL scint vial, and MeOH was added (3.0 mL). The suspension was stirred with a magnetic stirrer at room temperature overnight. The suspension was filtered and washed with MeOH (2.0 mL). The solids were dried at 45°C under vacuum for about 5 hours and then dissolved at reflux in MeOH (50 mL). The solution was allowed to cool and placed in a refrigerator at about 5°C for 5 days. The resulting solids were collected by filtration after reducing the solvent volume using a rotovap to yield Form B Methanol.

[00518] The XRPD scan is shown in Figure 2 and the peak assignments are in Table 2:

TABLE 2

2θ	d (Å)	Relative Intensity	18.48	4.7971	25.6
6.881	12.836	6.9	19.72	4.4982	39.9
8.46	10.4428	68.3	20.799	4.2672	53.5
8.838	9.997	32.9	21.143	4.1987	37.6
9.98	8.8555	100	21.622	4.1067	44.3
10.297	8.5837	29.3	23.161	3.8371	49.4
11.448	7.7236	10.1	23.579	3.7701	18.1
12.917	6.8483	9.8	24.72	3.5986	59.5
13.438	6.5839	72.7	25.519	3.4877	84.4
14.124	6.2653	9.6	27.736	3.2137	6.2
15.802	5.6037	39.5	28.278	3.1533	9.8
16.243	5.4526	22.9	30.063	2.9701	20.2
16.981	5.2171	60.7	32.469	2.7553	6.4
17.4	5.0925	23.8	33.173	2.6984	7.6
18.042	4.9128	53	33.926	2.6402	6.9
			34.484	2.5988	7.9

Example 3*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol Isomorphic Solvate

[00519] Absolute ethanol (8.5 L) (10-16 mL/g) was added to a vial containing a mixture of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine polymorphs (553 g; prepared as described above in Synthesis of Compounds section) and then heated to 70°C. The suspension was cooled to room temperature and agitated for over 12 hours. The suspension was filtered and washed twice with absolute ethanol (2 X 670 mL). The solids were dried in a vacuum oven at between 55°C and 60°C at 40 torr with a nitrogen bleed to yield Form B Ethanol (74.3% yield).

[00520] The XRPD scan is shown in Figure 3 and the peak assignments are in Table 3:

TABLE 3

2θ	d (Å)	Relative Intensity	21.04	4.219	29.1
8.358	10.5709	20.9	21.502	4.1293	46.3
8.752	10.095	4.6	22.402	3.9654	9
9.859	8.9643	56.6	22.801	3.897	8
10.217	8.6507	7.9	23.08	3.8505	38.5
10.748	8.2247	3.1	23.444	3.7915	15.1
11.394	7.7598	5.5	24.019	3.702	3.5
13.3	6.6515	50	24.278	3.6631	4.3
13.886	6.3722	5.1	24.621	3.6128	71.9
15.642	5.6607	25.4	25.419	3.5013	100
15.94	5.5555	6.5	25.785	3.4523	6
16.862	5.2539	38.4	26.202	3.3983	12.3
17.298	5.1224	19.2	28.275	3.1537	5
17.94	4.9404	39.8	28.978	3.0788	4.7
18.195	4.8718	26.1	29.94	2.982	15.1
18.384	4.822	12.7	30.764	2.904	4.8
19.342	4.5853	5.8	31.196	2.8648	2.1
19.602	4.5252	38.8	32.057	2.7897	4.2
20.718	4.2838	51.5	32.959	2.7154	5.3
			33.635	2.6624	4.6

34.102	2.627	5.8
35.006	2.5612	5.4
35.621	2.5184	5.1
37.3	2.4088	2.5

38.258	2.3506	7.6
38.935	2.3113	2.9
39.578	2.2752	4.3

Example 4

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Isopropyl Alcohol Isomorphic Solvate
[00521] IPA (50 mL) was added to a flask containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A (5.0 g) and was heated to reflux. Additional IPA (20 mL) was added and continued to heat at reflux. The solution was left stirring and allowed to cool to room temperature and then stored in a refrigerator overnight. The suspension was filtered and dried at room temperature to yield Form B Isopropyl Alcohol.

[00522] The XRPD scan is shown in Figure 4 and the peak assignments are in Table 4:

TABLE 4

2θ	d (Å)	Relative Intensity
8.283	10.6656	41.6
8.661	10.2012	7.5
9.78	9.0365	95.7
10.273	8.6041	15.8
11.34	7.7963	11.1
13.201	6.7013	65.7
13.879	6.3757	8.2
15.498	5.7128	24.3
15.9	5.5694	6.1
16.88	5.2482	100
17.24	5.1394	15.1
17.899	4.9515	88
18.378	4.8237	25.8
19.259	4.6049	34.5
19.542	4.5389	25.2

20.6	4.3081	97.5
21.202	4.1872	48.1
21.48	4.1336	33.8
22.2	4.0011	7.8
22.981	3.8669	48
23.38	3.8017	10.8
24.198	3.675	45.9
24.582	3.6185	48.2
25.082	3.5475	67.8
25.362	3.5089	66.2
25.802	3.4501	7.3
26.239	3.3937	9.2
27.981	3.1862	4.9
29.879	2.988	21.5
31.884	2.8045	4.3
32.977	2.714	8.3
34.024	2.6329	6.6

34.985	2.5627	6
35.618	2.5186	6.9
36.354	2.4693	5.5

36.866	2.4361	3.9
38.082	2.3611	5.5

Example 5

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetonitrile Isomorph Solvate

[00523] ACN (4 mL) was added to a 20 mL scint vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (647.9 mg), and the suspension was stirred magnetically at room temperature overnight. The suspension was filtered and washed with ACN (2 mL). The solids were dried at 45°C under vacuum for about 5 hours to yield Form B Acetonitrile.

[00524] The XRPD scan is shown in Figure 5 and the peak assignments are in Table 5:

TABLE 5

2θ	d (Å)	Relative Intensity
8.46	10.4428	43.2
8.818	10.0203	15.3
9.98	8.8559	95.3
10.899	8.1114	8.3
13.46	6.5729	55.5
14.163	6.2484	9.6
15.82	5.5973	18.1
16.921	5.2357	56.3
17.442	5.0805	31.3
18.12	4.8916	46.4
18.438	4.808	28.4
19.426	4.5657	5.8
19.842	4.471	35

20.821	4.2629	30.4
21.239	4.1798	35.2
21.741	4.0844	50.1
22.64	3.9243	11.3
23.319	3.8116	38.5
24.899	3.5731	61.5
25.661	3.4687	100
26.464	3.3653	18.7
28.283	3.1528	6.3
30.16	2.9607	16.6
31.946	2.7992	3.8
32.438	2.7579	4.8
33.042	2.7088	7.2
33.944	2.6389	9
34.539	2.5947	6.8

Example 6*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Acetone Isomorphic Solvate

[00525] Acetone (1 mL) was added to a 20 mL scint vial containing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine (113.0 mg), and the suspension was stirred with a magnetic stirrer at room temperature for about 2 hours. *N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (503.5 mg) and acetone (2 mL) were added, and the suspension was magnetically stirred at room temperature overnight. The suspension was filtered and washed with acetone (2 mL). The solids were dried at 45°C under vacuum for about 5 hours. The solids were slurried at reflux in acetone (100 mL), allowed to cool and stored in a refrigerator at about 5°C for over 5 days. The solvent was removed by rotovap, and the solids were collected by filtration to yield Form B Acetone.

[00526] The XRPD scan is shown in Figure 6 and the peak assignments are in Table 6:

TABLE 6

2θ	d (Å)	Relative Intensity			
5.785	15.2648	7.3	19.068	4.6506	3.9
8.378	10.5448	45.5	19.758	4.4897	37.6
8.678	10.1814	11.3	20.302	4.3706	31.7
9.936	8.8948	100	20.759	4.2754	27.2
10.342	8.547	10.7	21.041	4.2188	33
10.778	8.202	3.7	21.821	4.0698	32.2
11.481	7.7015	15.6	22.481	3.9518	18
13.041	6.7832	40.3	23.14	3.8406	18.6
13.378	6.613	27.8	23.498	3.783	35.8
14.12	6.267	8.3	24.679	3.6045	60.2
15.461	5.7265	12.4	25.52	3.4875	85.2
16.119	5.4942	5.3	26.312	3.3843	5
17.02	5.2052	70.8	26.641	3.3434	6.1
17.98	4.9295	49.9	28.119	3.1709	7.7
18.478	4.7977	27.5	28.985	3.0781	3.8
			30.061	2.9703	15.2
			32.099	2.7862	4

33.016	2.7109	3.9
--------	--------	-----

33.757	2.653	3.9
--------	-------	-----

Example 7

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Dichloromethane Isomorphic Solvate

[00527] DCM (1 mL) was added to a 20 mL scint vial containing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine (181.7 mg), and the suspension was stirred with a magnetic stirrer at room temperature for about 2 hours. *N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (506.3 mg) and DCM (2 mL) were added, and the suspension was magnetically stirred at room temperature overnight. The suspension was filtered and washed with DCM (2 mL). The solids were dried at 45°C under vacuum for about 5 hours. The solids were slurried at reflux in DCM (5 mL), allowed to cool and stored in a refrigerator at about 5°C for over 5 days. The solids were collected by filtration to yield Form B Dichloromethane.

[00528] The XRPD scan is shown in Figure 7 and the peak assignments are in Table 7:

TABLE 7

2θ	d (Å)	Relative Intensity
7.96	11.0985	28
8.439	10.4697	55.9
8.817	10.0216	12.6
9.517	9.2861	19
9.977	8.8582	84.5
10.265	8.6109	29.3
11.47	7.7085	18.5
12.579	7.0311	21.8
13.381	6.6116	88.6
15.796	5.6059	32.4
16.918	5.2364	100
17.438	5.0814	37.3

18.041	4.9128	57.4
18.34	4.8335	45.8
19.336	4.5867	18.1
19.899	4.4582	48
20.738	4.2797	81.9
21.161	4.1951	38.9
21.802	4.0732	44.8
23.46	3.789	48.8
24.779	3.5902	72.2
25.641	3.4715	75.3
26.441	3.3681	16.4
28.27	3.1543	16.5
30.319	2.9456	16.3
34.536	2.5949	11.3

Example 8

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Tetrahydrofuran Isomorphous Solvate

[00529] THF (4 mL) was added to a vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran (300 mg), and the contents were agitated at room temperature. The contents were filtered and washed with THF (3 X 0.8 mL). The solids were dried in a vacuum oven at 45°C with a nitrogen bleed to yield Form B Tetrahydrofuran (91.8% yield).

[00530] The XRPD scan is shown in Figure 8 and the peak assignments are in Table 8:

TABLE 8

2θ	d (Å)	Relative Intensity	21.4	4.1489	58.7
8.262	10.6932	33	22.92	3.877	40.7
8.679	10.1799	15.5	24.66	3.6072	64
9.819	9.0002	84.9	25.44	3.4984	100
10.718	8.2473	7.1	26.079	3.414	20.6
13.38	6.6123	61.1	28.28	3.1532	4.1
13.96	6.3388	12.5	29.84	2.9918	13.8
15.72	5.6327	22.4	32.237	2.7746	3.9
16.7	5.3042	65.3	32.781	2.7298	5.2
17.179	5.1575	26.2	33.7	2.6574	7.7
17.92	4.9459	70.9	35.262	2.5432	7.2
19.541	4.5392	30.8	37.296	2.4091	2.6
20.58	4.3121	21.6	38.335	2.3461	3.8
			39.4	2.2851	2.2

Example 9

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Anhydrous

[00531] *N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol (1.10 g) was placed in a watch glass, which was then placed in an oven at 100°C with nitrogen flowing through it. The solid was removed after 5 days and placed in a 25 mL round bottom flask and

heated to 200°C under high vacuum for 1 hour. The sample was again placed in the oven at 200°C under high vacuum for 3 hours. The solids were collected in a 20 mL scint vial to yield Form B Anhydrous.

[00532] The XRPD scan is shown in Figure 9 and the peak assignments are in Table 9:

TABLE 9

2θ	d (Å)	Relative Intensity			
8.44	10.4679	37.8	23.538	3.7766	14.6
8.855	9.9777	18.7	24.901	3.5729	35.1
9.938	8.8932	100	25.541	3.4848	60.4
10.902	8.1086	9	26.159	3.4038	13.6
12.642	6.9962	2.4	28.078	3.1754	1.7
13.641	6.4863	54.2	28.558	3.1231	2.9
14.28	6.1975	12.4	29.213	3.0545	2.4
16.016	5.5294	25.5	29.879	2.9879	9.4
16.841	5.2602	43.8	30.242	2.9529	3.5
17.099	5.1813	37.1	31.379	2.8485	2.6
17.439	5.0813	27	31.845	2.8079	2.3
18.1	4.8971	54.1	32.416	2.7597	2.9
18.42	4.8127	22.9	32.944	2.7166	3.3
19.697	4.5035	25.8	33.943	2.6389	4.1
20.222	4.3877	5.8	34.657	2.5862	1.7
20.704	4.2867	11.1	35.463	2.5292	5.5
21.22	4.1835	42.8	37.385	2.4035	1.9
21.498	4.1301	45.6	38.582	2.3316	2.7
22.56	3.9381	4.1	39.558	2.2764	1.3
23	3.8636	24.7			

Example 10

N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C

[00533] 2-Methoxyethanol (200 mL) was added to a 500 mL Erlenmeyer flask containing N4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-

4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A (15.11 g), and the solution was heated to 50°C with stirring. The flask was cooled to room temperature, and the volume was reduced to about 50 mL by rotovap. The flask was allowed to stand for 2 hours. EtOH (200 mL) was added, and the contents of the flask were stirred, filtered and washed with EtOH (3 X 15 mL). The solid was dried at 50°C under vacuum overnight to yield Form C (Anhydrous).

[00534] The XRPD scan is shown in Figure 10 and the peak assignments are in Table 10:

TABLE 10

2θ	d (Å)	Relative Intensity			
5.04	17.52	100	22.34	3.9763	52.8
7.159	12.3378	69.6	22.878	3.884	24.6
10.159	8.7004	68.2	23.779	3.7389	32
11.376	7.772	16.2	24.181	3.6776	64.8
11.902	7.4299	29.8	24.58	3.6188	33.1
12.16	7.2724	9.2	25.262	3.5226	11
12.977	6.8163	17.9	25.679	3.4663	11
14.435	6.1313	76.8	26.096	3.4119	29.8
15.301	5.786	99.8	26.809	3.3228	5.8
15.717	5.6338	66.7	27.18	3.2783	19.1
16.121	5.4936	29.8	27.675	3.2208	8.4
16.719	5.2985	43.3	27.88	3.1975	8.6
17.501	5.0632	76.3	28.417	3.1383	16
18.059	4.908	36.8	28.599	3.1187	16.3
18.437	4.8084	88.4	30.021	2.9742	7.6
18.902	4.6911	90.7	31.113	2.8722	5.5
19.638	4.5168	74.1	31.863	2.8063	6.6
20.479	4.3333	30.7	32.674	2.7385	5.9
21.08	4.2111	42.2	33.339	2.6853	17.7
21.437	4.1418	42.3	34.234	2.6171	6
21.74	4.0848	27.8	34.878	2.5703	8.6
			37.442	2.4	8.9

Example 11

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Ethyl Acetate Isomorphous Solvate

[00535] EtOAc (2.0 mL) was added to a 4 mL vial containing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine (394 mg), and the contents were stirred overnight at room temperature. The solids were dried under a stream of nitrogen to yield Form D Ethyl Acetate.

[00536] The XRPD scan is shown in Figure 11 and the peak assignments are in Table 11:

TABLE 11

2θ	d (Å)	Relative Intensity			
5.596	15.7789	13.5	22.557	3.9386	7.6
6.741	13.1015	11	22.93	3.8753	5.9
7.959	11.0998	100	23.599	3.7669	38.3
9.139	9.669	3.4	24.241	3.6686	18.7
9.798	9.0196	38.7	25.34	3.512	13.7
11.321	7.8099	35.5	25.66	3.4689	15.5
12.66	6.9863	61.3	27.52	3.2385	33.6
13.917	6.3581	33.9	28.142	3.1684	5.4
16.099	5.501	54.8	28.724	3.1054	4.6
17.118	5.1757	48.3	29.023	3.0742	4.7
18.017	4.9194	33.9	29.359	3.0397	4.4
18.937	4.6825	6.4	30.045	2.9719	2.7
19.761	4.489	47.4	31.56	2.8326	4.8
21.379	4.1529	28.2	32.093	2.7867	3.8
22.139	4.012	23.9	32.701	2.7363	2.7
			33.243	2.6929	3.5
			37.161	2.4175	2.7

Example 12

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Dioxane Isomorphic Solvate

[00537] Dioxane (600 μ L) was added to a vial containing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine (90 mg), and the contents were allowed to stir overnight. The solids were filtered and dried at room temperature to yield Form D Dioxane.

[00538] The XRPD scan is shown in Figure 12 and the peak assignments are in Table 12:

TABLE 12

2 θ	d ($\text{\AA}$)	Relative Intensity			
7.822	11.294	99.1	17.703	5.0059	35
9.34	9.4615	30.3	19.54	4.5394	100
9.759	9.0562	33.4	21.062	4.2146	84.1
11.139	7.9369	98.7	21.901	4.0551	28
12.5	7.0753	86.2	23.139	3.8409	89.2
13.378	6.6132	16.1	24.022	3.7016	53
13.763	6.429	32.4	25.202	3.5309	33.4
15.841	5.5899	17	27.179	3.2784	62.6
16.461	5.3808	32.6	28.859	3.0912	18.6
17.135	5.1708	43.3	37.578	2.3916	9.4
			39.493	2.2799	9.1

Example 13

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Acetone Isomorphic Solvate

[00539] Acetone (300 μ L) was added to a vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (100 mg), and the contents were allowed to stir overnight. The solids were filtered and dried at room temperature to yield Form D Acetone.

[00540] The XRPD scan is shown in Figure 13 and the peak assignments are in Table 13:

TABLE 13

2 θ	d (Å)	Relative Intensity			
5.656	15.6134	10.8	25.339	3.5121	21.6
7.999	11.0445	100	25.622	3.474	29.3
8.603	10.2695	2.9	26.981	3.3019	11.2
9.856	8.9671	43.6	27.482	3.2429	82.1
11.359	7.7837	33.7	28.122	3.1705	15.5
12.681	6.9748	48.3	28.723	3.1056	13.1
13.923	6.3555	55.6	29.002	3.0763	10.1
16.101	5.5003	59.5	29.339	3.0417	11.7
17.14	5.169	83.3	29.848	2.991	4.3
17.625	5.0278	6.4	30.2	2.9569	4.1
18	4.9241	36.7	31	2.8824	3.8
18.941	4.6815	13.8	31.539	2.8344	5.1
19.761	4.489	56.4	32.041	2.7911	10.8
20.581	4.3121	7.2	32.662	2.7395	9.3
21.378	4.153	63	33.218	2.6949	7.6
22.103	4.0185	38.1	33.611	2.6642	3.6
22.541	3.9413	13.9	35.201	2.5474	4.1
22.9	3.8804	16	35.675	2.5147	3.1
23.561	3.7729	71.5	37.117	2.4203	8
24.259	3.6659	42.6	39.058	2.3043	6
25.063	3.5501	5.8			

Example 14

N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form D Propyl Acetate Isomorphous Solvate

[00541] Propyl acetate (400 μ L) was added to a vial containing N4-(4-[1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (50 mg), and the contents were allowed to stir overnight. The solids were filtered and dried at room temperature to yield Form D Propyl Acetate.

[00542] The XRPD scan is shown in Figure 14 and the peak assignments are in Table 14:

TABLE 14

2 θ	d (Å)	Relative Intensity			
5.074	17.4026	6.3	19.782	4.4844	68.7
5.623	15.7043	8.4	20.65	4.2977	7.7
7.189	12.2862	5.2	21.42	4.1449	38.6
7.999	11.0438	100	22.201	4.0008	33.5
9.839	8.9821	43.1	22.596	3.9318	16.5
10.158	8.7009	7.5	22.92	3.8771	15.1
11.362	7.7816	32.3	23.62	3.7637	61.7
12.719	6.9541	68.2	24.28	3.6629	45.7
13.903	6.3648	39.7	25.379	3.5066	26.7
14.381	6.1539	6.4	25.681	3.466	26.4
15.701	5.6395	10.3	27.579	3.2317	54.1
16.121	5.4937	68.2	28.825	3.0948	9.1
17.16	5.1633	84.4	29.137	3.0623	10.8
17.574	5.0423	8.5	29.365	3.0391	6.1
18.021	4.9183	38.5	31.503	2.8376	8.4
18.419	4.813	9.8	32.019	2.793	5.2
18.96	4.677	19.2	32.699	2.7364	6
			33.283	2.6898	7.8
			37.179	2.4164	4.6
			39.104	2.3017	5

Example 15

N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E

[00543] N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine was synthesized from 1-(4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea (322 g) in THF (3L) at 0°C. Water (10 L) was added, and the solution was allowed to stir for 1 hour, at which point the material oiled out. The organics were then extracted into ethyl acetate (3 X 5000 mL), combined and washed with

water (2 X 5000 mL) and brine (2 X 5000 mL). The organics were dried by rotoevaporation, and the material was concentrated to an oil. The oil was observed to solidify at room temperature to yield Form E.

[00544] The XRPD scan is shown in Figure 15 and the peak assignments are in Table 15:

TABLE 15

2θ	d (Å)	Relative Intensity			
8.659	10.204	44.5	21.296	4.1689	18.1
9.353	9.4482	38.4	21.62	4.107	12.6
10	8.8382	4.8	22.179	4.0047	1.8
11.904	7.4284	27.3	22.821	3.8935	18.4
12.416	7.123	14.8	23.739	3.745	43.6
12.923	6.8451	19.3	24.358	3.6512	6.7
15.36	5.7638	11	24.94	3.5674	2.7
16.06	5.5143	100	25.295	3.518	3
16.338	5.421	16.6	25.459	3.4958	2.5
16.709	5.3015	2.9	26.106	3.4107	3.5
16.918	5.2363	8	27.035	3.2955	3.6
17.457	5.0759	4.9	27.8	3.2065	6.8
18.03	4.9158	3.8	28.297	3.1513	15.4
18.4	4.8179	8.1	29.237	3.0521	2.3
19.021	4.6621	11.2	30.716	2.9084	2.7
19.619	4.5212	19.4	31.799	2.8118	4.9
20.08	4.4186	23.4	32.507	2.7522	1.7
20.656	4.2965	3.8	36.658	2.4495	1.9
			39.055	2.3045	1.5

Example 16

N4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form F

[00545] Ethyl acetate (5 mL) was added to a vial containing N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (1 g), and the contents were stirred for 48 hours. The solid was filtered

and dried overnight in a vacuum oven at room temperature to yield Form F (Ethyl Acetate solvate).

[00546] The XRPD scan is shown in Figure 16 and the peak assignments are in Table 16:

TABLE 16

2 θ	d (Å)	Relative Intensity			
6.981	12.6512	8.2	22.24	3.994	22.1
7.58	11.6541	15	22.537	3.942	35.1
8.24	10.7212	14.5	23.004	3.8631	16.3
9.483	9.3191	12.6	23.361	3.8047	9.3
11.04	8.008	4.5	23.996	3.7056	24.8
11.498	7.6901	32.5	24.423	3.6417	6.6
12.321	7.178	9.5	24.942	3.567	26
12.859	6.8787	12.4	25.379	3.5067	13.8
13.633	6.49	2.5	26.418	3.371	6.7
13.897	6.3675	2.7	26.738	3.3314	4.4
14.899	5.9413	41.3	27.34	3.2594	25.3
15.906	5.5673	4.1	27.913	3.1938	4.3
16.56	5.3487	100	28.38	3.1423	5.4
16.92	5.2357	50.2	29.02	3.0744	15.7
18.502	4.7916	14.9	29.915	2.9844	4.6
19.098	4.6433	87.8	31.941	2.7996	4.5
19.62	4.5209	32.4	33.417	2.6793	4.5
20.663	4.2952	12.9	35.201	2.5475	4.8
21.18	4.1914	35.4	36.042	2.4899	2.8
21.633	4.1046	8			

Example 17

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran Isomorphic Solvate

[00547] THF:water (2 mL, 20:80) was added to a vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran (100 mg), and the contents were stirred at room temperature overnight. The contents were then heated to 40°C and stirred overnight. The solids were filtered and collected to yield Form G hemi-Tetrahydrofuran.

[00548] The XRPD scan is shown in Figure 17 and the peak assignments are in Table 17:

TABLE 17

2θ	d (Å)	Relative Intensity	18.837	4.7072	15.6
5.148	17.1528	3.5	19.26	4.6047	16.8
5.521	15.995	13.1	19.72	4.4982	19.6
7.719	11.4438	91.4	20.26	4.3795	22.6
8.018	11.0172	28.3	20.645	4.2989	5.3
9.379	9.4216	28.6	21.022	4.2225	30.3
11.102	7.963	42.1	21.243	4.1792	22.2
12.281	7.201	49.9	21.865	4.0617	7.5
12.737	6.9445	17.6	22.6	3.9311	9.2
13.263	6.67	13.8	23.079	3.8507	100
13.897	6.3673	3.3	23.359	3.8052	34.1
14.097	6.2772	5.9	24.099	3.69	55.8
15.558	5.6909	20.2	24.48	3.6333	11.5
16.142	5.4863	16.5	24.934	3.5683	6.3
16.544	5.3541	32.6	25.222	3.5281	10.7
16.955	5.2253	10.4	26.839	3.3191	17.6
17.26	5.1336	16.1	27.282	3.2662	16.1
17.519	5.0583	17.4	27.503	3.2404	37.7
18.096	4.8982	16.6	28.281	3.1531	6.7
			28.52	3.1272	7.7

29.062	3.07	6.3
29.814	2.9943	9

31.297	2.8558	4.3
32.39	2.7619	5.4

Example 18

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran Isomorphic Solvate

[00549] THF (150 mL) was added to a flask containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A (5.17 g), and the contents were heated to reflux until all of the solids dissolved. The heat was removed, and the flask was allowed to cool to room temperature with stirring overnight. The volume was reduced to about 50 mL by nitrogen evaporation. The flask was stored in a refrigerator overnight. The contents of the flask were filtered and washed with THF (2 X 10 mL). The solids were dried at 50°C under vacuum overnight to yield Form G mono-Tetrahydrofuran.

[00550] The XRPD scan is shown in Figure 18 and the peak assignments are in Table 18:

TABLE 18

2θ	d (Å)	Relative Intensity
5.522	15.9921	20.2
7.72	11.4432	87.8
8.003	11.039	45.6
9.417	9.3841	39.8
11.137	7.9379	60.5
12.401	7.1321	58.8
12.734	6.946	24.7
13.281	6.6612	16.6
13.825	6.4002	4.9
14.083	6.2837	9.5
15.559	5.6908	19.6
16.159	5.4806	19.6
16.599	5.3365	44.8

16.961	5.2233	18.7
17.318	5.1164	27.2
17.54	5.0521	18.3
18.14	4.8864	22.5
18.858	4.702	19.9
19.3	4.5952	17.8
19.739	4.4939	27.1
20.257	4.3802	21.8
21.017	4.2235	40.5
21.24	4.1796	29.3
22.601	3.9309	12.2
23.022	3.8601	100
23.397	3.799	38.6
24.042	3.6985	77.4
24.419	3.6423	11.8

25.222	3.5281	9.6
26.82	3.3214	23.9
27.482	3.2429	38.2
28.463	3.1333	10.5

29.06	3.0703	8.2
29.8	2.9957	8.5
30.664	2.9132	5.6
32.382	2.7625	7

Example 19

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Isopropyl Acetate Isomorphous Solvate
[00551] Isopropyl acetate (5 mL) was added to a vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (500 mg), and the contents were stirred at room temperature for 48 hours. The contents were filtered and dried overnight in a vacuum oven at room temperature to yield Form G Isopropyl Acetate.

[00552] The XRPD scan is shown in Figure 19 and the peak assignments are in Table 19:

TABLE 19

2θ	d (Å)	Relative Intensity
5.601	15.765	18.2
7.803	11.3215	61.8
8.299	10.6452	55.3
9.361	9.4403	52.3
9.841	8.9804	11.8
11.398	7.7568	59.8
12.7	6.9646	49.6
13.18	6.712	52.7
14.026	6.3092	5
15.961	5.5483	34.8
16.64	5.3232	52.6
17.121	5.1748	28.6
17.457	5.076	10.6
18.099	4.8973	36.6
18.655	4.7526	22.1

19.04	4.6573	17.9
19.639	4.5166	38.4
19.979	4.4405	49.1
20.58	4.3122	26.8
21.323	4.1636	17.8
21.738	4.0851	46.5
22.58	3.9345	27.7
23.438	3.7924	100
23.739	3.745	32.1
24.381	3.6478	51.6
24.737	3.5961	34.4
25.084	3.5472	12.2
26.605	3.3478	10.1
27.821	3.2042	46.9
29.303	3.0454	6.8
29.899	2.986	14.5
31.171	2.867	5.3

31.641	2.8255	8.5
32.799	2.7283	5.4

33.295	2.6888	6
38.788	2.3197	6.4

Example 20

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Methyl Isobutyl Ketone Isomorphic Solvate

[00553] MIBK (400 μ L) was added to a vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (50 mg), and the suspension was stirred at room temperature overnight. The solids were filtered and dried to yield Form G Methyl Isobutyl Ketone.

[00554] The XRPD scan is shown in Figure 20 and the peak assignments are in Table 20:

TABLE 20

2 θ	d (Å)	Relative Intensity
4.824	18.302	12.3
5.638	15.6616	26.6
7.78	11.3544	95.5
8.217	10.7513	58.1
9.298	9.5039	50.4
11.239	7.8665	72.1
11.515	7.6787	13.8
12.341	7.1661	46.1
12.575	7.0334	46.9
13.079	6.7636	50.2
13.437	6.5842	19
14.338	6.1723	16.4
15.715	5.6346	16.1
16.221	5.4599	29.8
16.503	5.3672	69.4
16.993	5.2135	28.4
17.415	5.0881	25.4

17.961	4.9347	29.2
18.503	4.7914	32.5
19.036	4.6585	24.8
19.35	4.5835	21.3
19.66	4.512	22.7
19.858	4.4674	52
20.52	4.3247	24
21.221	4.1834	27.4
21.442	4.1408	50
21.641	4.1032	28.3
22.305	3.9825	25.8
22.644	3.9236	16.1
23.28	3.8178	100
23.619	3.7637	46.7
24.562	3.6214	56.6
24.997	3.5593	23.7
27.477	3.2435	27.1
27.759	3.2111	50.5
28.302	3.1508	23.6

29.898	2.9862	17.4
31.866	2.806	14.3

33.135	2.7014	10.4
--------	--------	------

Example 21

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form H

[00555] MTBE (600 μ L) was added to a vial containing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine (90 mg), and the contents were stirred at room temperature overnight. The solids were filtered and dried at room temperature to yield Form H (Methyl *tert*-Butyl Ether solvate).

[00556] The XRPD scan is shown in Figure 21 and the peak assignments are in Table 21:

TABLE 21

2 θ	d ($\text{\AA}$)	Relative Intensity
7.38	11.9685	14.9
9.246	9.5576	11.1
11.18	7.908	100
12.701	6.9638	12.2
16.08	5.5075	55.8
18.696	4.7422	9.9
19.58	4.5302	30.1

22.04	4.0298	73.9
24.741	3.5955	21.7
25.501	3.4901	29.6
26.738	3.3314	13.3
27.86	3.1997	11.7
28.198	3.1621	7.5
31.901	2.803	7.3
33.618	2.6637	7.8

Example 22

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form I

[00557] Xylene (600 μ L) was added to a vial containing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine (90 mg), and the contents were stirred at room temperature overnight. The solids were filtered and dried at room temperature to yield Form I (Xylenes solvate).

[00558] The XRPD scan is shown in Figure 22 and the peak assignments are in Table 22:

TABLE 22

2 θ	d (Å)	Relative Intensity			
4.318	20.4483	11.8	18.303	4.8434	59.5
7.2	12.268	100	18.904	4.6907	24.3
8.065	10.9535	33.7	19.32	4.5905	39.8
8.421	10.4921	19.4	19.54	4.5394	39.6
9.603	9.2023	8.9	20.261	4.3794	33.3
10.343	8.5459	34.1	20.641	4.2997	35.9
11.101	7.9636	33.8	21.082	4.2107	27.8
12.117	7.2984	37.7	22.282	3.9866	40.3
12.664	6.9844	20.2	23.101	3.8471	44
13.057	6.7751	17.4	23.942	3.7137	21.6
14.961	5.9169	22.7	25.134	3.5403	7.6
15.222	5.816	28.1	25.541	3.4847	20.7
16.319	5.4272	35.3	26.341	3.3807	27.7
16.559	5.3491	64.2	27.198	3.2761	9.2
16.798	5.2735	27.6	27.395	3.2529	9.6
17.578	5.0414	19.1	27.667	3.2216	7.4
			29.58	3.0174	9.7

Example 23

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form J

[00559] 2-Methoxyethanol (4 mL) was added to a 20 mL scint vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (1013.25 mg), and the contents were stirred at room temperature for about 6 hours. The contents were filtered and washed with 2-methoxyethanol (2 X 10 mL). The solids were dried on the filter at room temperature for about 1 hour to yield Form J (2-Methoxyethanol solvate).

[00560] The XRPD scan is shown in Figure 23 and the peak assignments are in Table 23:

TABLE 23

2 θ	d (Å)	Relative Intensity			
4.019	21.9675	4.5	24.062	3.6955	15.2
4.479	19.7134	53.2	24.658	3.6076	16.7
6.777	13.0322	25.4	24.957	3.5649	16.9
8.982	9.838	49.8	25.664	3.4683	21.4
10.358	8.5335	3.2	26.167	3.4028	6.4
11.874	7.4469	2.4	26.734	3.3319	6
12.083	7.319	4.5	26.998	3.2999	4.1
12.724	6.9517	18.9	27.299	3.2642	16.3
13.521	6.5434	29.6	27.497	3.2411	9.8
14.463	6.1192	4.7	27.638	3.2249	6.9
15.014	5.896	6.2	28.779	3.0996	2.7
16.963	5.2228	100	30.02	2.9742	4.9
18.078	4.903	88.2	31.106	2.8729	3.1
18.797	4.7169	39.4	32.043	2.791	10.5
19.317	4.5912	11.4	33.279	2.69	4.5
19.858	4.4673	32.5	33.604	2.6648	4.6
20.156	4.4019	25.4	34.407	2.6044	4.4
20.838	4.2595	23.3	35.097	2.5548	3.2
21.761	4.0808	31.2	36.444	2.4634	4.4
22.118	4.0158	9.4	36.655	2.4497	2.8
22.682	3.9171	12.9	37.891	2.3726	2.2
23.298	3.8149	19	38.179	2.3553	2.9
			38.459	2.3388	2.3
			39.413	2.2844	2.2

Example 24

N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form K

[00561] DME (4 mL) was added to a 20 mL scint vial containing N4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (939.4 mg), and the contents were stirred at room temperature for about 6 hours. The contents were filtered and washed with

DME (2 X 10 mL). The solids were dried at 50°C under vacuum overnight to yield Form K (Dimethoxyethane solvate).

[00562] The XRPD scan is shown in Figure 24 and the peak assignments are in Table 24:

TABLE 24

2 θ	d (Å)	Relative Intensity			
6.923	12.7574	32.9	22.78	3.9005	100
8.499	10.3956	8.4	23	3.8638	77.9
10.137	8.7186	3.2	23.336	3.8088	3.8
11.036	8.011	12.5	23.863	3.7259	3.6
11.836	7.4712	28.8	24.205	3.674	7.1
12.054	7.3363	4.3	24.503	3.63	8.2
12.743	6.9411	10.2	25.269	3.5217	4.2
13.259	6.6723	5.8	25.701	3.4635	42.8
13.923	6.3553	38.8	27.101	3.2876	27.3
14.775	5.9908	10.3	28.26	3.1554	6
15.797	5.6056	62.7	28.821	3.0952	5.8
16.96	5.2237	20.8	29.258	3.0499	4.2
17.16	5.1632	31.8	29.441	3.0314	6.6
17.62	5.0293	58.8	29.864	2.9894	4.5
17.998	4.9246	34.6	30.444	2.9338	5.6
18.482	4.7967	3.2	30.749	2.9054	2.5
18.683	4.7455	8	31.942	2.7995	5.5
18.999	4.6673	39.5	32.94	2.7169	2.8
21.041	4.2187	4.9	33.864	2.6449	4.3
21.24	4.1797	9.2	35.505	2.5264	2.3
21.796	4.0744	4.8	36.018	2.4915	3.3
21.898	4.0555	4.7	37.375	2.4041	2.3
22.177	4.0051	4.5	38.245	2.3514	2.3
			38.876	2.3147	2.4
			39.333	2.2888	2.4

Example 25

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form L

[00563] MeOAc (400 μ L) was added to a vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E (50 mg), and the contents were stirred overnight at room temperature. The solids were filtered and dried to yield Form L (Methyl Acetate solvate).

[00564] The XRPD scan is shown in Figure 25 and the peak assignments are in Table 25:

TABLE 25

2 θ	d ($\text{\AA}$)	Relative Intensity			
5.028	17.5604	5.3	21.462	4.137	20.3
6.978	12.657	10.4	22.122	4.015	9.2
7.602	11.6193	13.4	22.457	3.9558	47.9
8.301	10.6435	15.1	23.019	3.8606	15.7
9.34	9.4614	5.5	23.661	3.7572	7.4
9.638	9.1691	3.5	24.126	3.6859	7.3
11.523	7.673	22.9	24.6	3.6159	16.9
12.281	7.2015	3.5	25.7	3.4636	16.9
12.758	6.9332	20.1	26.311	3.3845	7.2
14.899	5.9414	64.5	27.183	3.2779	17.1
15.463	5.7257	10.4	27.819	3.2044	11.7
16.198	5.4675	12.2	28.64	3.1144	12.5
16.98	5.2176	100	29.736	3.002	6.2
17.521	5.0575	9.1	30.939	2.888	5.1
18.478	4.7978	12.7	31.197	2.8647	4.3
18.958	4.6773	89.8	32.037	2.7915	5.7
19.62	4.5211	27.2	32.379	2.7627	6.1
20.822	4.2627	16.4	32.742	2.7329	4.9
21.062	4.2147	37.3	33.764	2.6525	4.5
			35.919	2.4981	3.8
			38.746	2.3222	3.3

Example 26

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form M

[00565] THF:water (0.4 mL, 1:1) was added to a flask containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol (50 mg), and the contents were stirred for 24 hours at room temperature. The solids were filtered and dried at room temperature to yield Form M (Tetrahydrofuran:Water solvate) (86% yield).

[00566] The XRPD scan is shown in Figure 26 and the peak assignments are in Table 26:

TABLE 26

2θ	d (Å)	Relative Intensity			
8.982	9.8379	100	22.583	3.9341	15.8
10.375	8.5192	24.7	23.083	3.8501	68.1
11.194	7.8982	4.2	23.455	3.7897	13.6
13.379	6.6124	13.3	23.863	3.7259	3.6
14.422	6.1366	7.7	24.419	3.6422	4.4
15.136	5.8487	34.5	24.715	3.5993	4.2
15.561	5.6899	26.3	24.943	3.5669	4.9
16.057	5.5153	8.5	25.438	3.4987	3.3
16.255	5.4484	10.3	25.822	3.4474	3.8
17.009	5.2086	3.6	26.44	3.3683	5.2
17.383	5.0975	3.7	26.76	3.3287	29.9
17.859	4.9625	7.4	27.301	3.2639	6.8
18.201	4.8702	23.4	28.126	3.17	2.9
18.54	4.7819	7.5	29.178	3.0581	6
18.819	4.7115	7.8	29.459	3.0296	13.8
20.738	4.2798	47.8	30.543	2.9245	8.5
21.395	4.1497	21.8	32.507	2.7522	3.1
			34.461	2.6005	3.3

Example 27*N4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form N*

[00567] A solution of 1% NaCMC and 0.1% Tween® in water (2 mL) was added to a vial containing *N4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol* (51.26 mg). The vial was placed on a stir plate and allowed to stir for 2 weeks at room temperature. Solids were collected by filtration and washed with water (2 X 3 mL). The solids were collected and dried under vacuum at room temperature overnight to yield Form N (Hydrate).

[00568] The XRPD scan is shown in Figure 27 and the peak assignments are in Table 27:

TABLE 27

2θ	d (Å)	Relative Intensity			
7.04	12.5463	33.6	21.302	4.1676	11.2
8.142	10.8505	9.2	21.895	4.0561	3.6
8.521	10.3682	15.6	22.92	3.877	100
8.902	9.9256	6.9	24.074	3.6937	4.8
10.238	8.6335	8.5	24.701	3.6013	10.9
11.16	7.9217	14.5	25.881	3.4398	41.7
11.941	7.4055	29	27.319	3.2618	29.9
12.918	6.8476	9.5	28.401	3.14	8.5
13.36	6.6221	7.4	28.999	3.0766	5.5
14.02	6.3115	36.9	29.539	3.0216	6
14.903	5.9398	9.6	30.041	2.9722	4.9
15.88	5.5764	66.7	30.578	2.9213	5.8
17.378	5.0988	32.6	32.138	2.7829	5
17.759	4.9903	53.9	33.081	2.7057	5.1
18.08	4.9025	35.3	34.001	2.6346	4.7
19.202	4.6185	40.1	35.623	2.5183	3.8
			36.195	2.4797	4.8
			37.291	2.4093	2.3

Example 28

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form O

[00569] THF (40 g) was added to a vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran (3 g), and the contents were agitated at 50°C. The contents were filtered and washed with THF (3 X 6 mL). Solids were dried in a vacuum oven at 45°C with a nitrogen bleed to yield Form O (Anhydrous) (45% yield).

[00570] The XRPD scan is shown in Figure 28 and the peak assignments are in Table 28:

TABLE 28

2θ	d (Å)	Relative Intensity	19.198	4.6193	9.3
8.161	10.825	10.4	19.98	4.4404	36.8
8.875	9.9558	6	21.243	4.1791	6.8
9.361	9.4402	4.7	22.179	4.0048	59.7
9.96	8.8737	3.5	22.677	3.9179	19.2
10.522	8.4007	9.9	23.141	3.8405	20.9
11.238	7.8669	100	24.86	3.5786	18.7
12.722	6.9528	6.4	25.638	3.4718	25.8
13.541	6.534	10.6	26.861	3.3164	8.1
15.043	5.8845	7.4	27.979	3.1864	10.1
15.544	5.6961	8.7	28.376	3.1427	4.7
16.079	5.5079	21	30.583	2.9208	6
16.52	5.3618	41	31.917	2.8017	4.5
17.63	5.0266	5.6	32.657	2.7398	2.2
18.701	4.741	6.7	33.861	2.6451	5.3

Example 29

*N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form P

[00571] Water (12 mL) was added to a vial containing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-

4,6-diamine Form G Tetrahydrofuran (1.5 g), and the contents were agitated at room temperature. The contents were filtered and washed with THF:water (1:2.2 v/v. 7.2 mL) and water (7.2 mL). The wet cake was dried in a vacuum oven at 55°C with a nitrogen bleed to yield Form P (Anhydrous) (81% yield).

[00572] The XRPD scan is shown in Figure 29 and the peak assignments are in Table 29:

TABLE 29

2 θ	d (Å)	Relative Intensity			
6.962	12.687	5.1	24.76	3.5929	17.9
9.901	8.9266	38.5	25.359	3.5093	8.3
11.043	8.0059	25.4	26.982	3.3018	10.3
11.422	7.7411	1.4	27.619	3.2271	11.9
12.48	7.0867	1.7	28.419	3.138	5.2
13.123	6.7412	6.9	29.022	3.0742	6.1
13.74	6.4396	28.6	29.923	2.9837	9.1
14.577	6.0716	10.9	30.781	2.9024	6.3
15.403	5.7481	20.5	31.72	2.8186	4.6
15.662	5.6536	48.4	32.044	2.7909	3
16.424	5.3929	13.9	32.314	2.7682	2.2
17.661	5.0179	32	33.441	2.6774	3.2
18.777	4.7221	6.7	34.377	2.6066	5.8
19.92	4.4537	8.1	35.815	2.5052	2.6
20.541	4.3204	22.4	36.376	2.4678	3.4
21.684	4.0951	4.3	37.083	2.4224	2.1
22.14	4.0118	11.7	38.365	2.3443	1.8
23.04	3.857	14.6	38.827	2.3175	2.1
23.5	3.7826	100	39.437	2.283	3.1
24.271	3.6641	1.8			

Example 30

Amorphous *N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine

[00573] *N*4-(4-([1,2,4]Triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol (402 mg) was added to a vial containing 3:7 water:THF (40 mL). The solution was sonicated and stirred until all the solids were dissolved. The solution was then frozen in a dry ice/acetone bath (4 hours) and lyophilized over a period of 48 hours to yield an amorphous powder.

[00574] The XRPD scan is shown in Figure 30.

Example 31Pharmaceutical Composition

[00575] A pharmaceutical composition may be prepared by forming a powder in capsule ("PIC") composition containing 25 mg or 100 mg of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine from Examples 1 to 30. The PIC composition may be prepared in size 00 white opaque hard gelatin capsules.

[00576] It will be understood that the enumerated embodiments are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications and equivalents, which may be included within the scope of the present invention as defined by the claims. Thus, the foregoing description is considered as illustrative only of the principles of the invention.

[00577] The words "comprise," "comprising," "include," "including," and "includes" when used in this specification and in the following claims are intended to specify the presence of stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, or groups thereof.

CLAIMS

1. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine freebase.
2. The crystalline polymorph of Claim 1, wherein the polymorph is Form A.
3. The crystalline polymorph of Claim 2, wherein said polymorph has an XRPD pattern substantially the same as Figure 1.
4. The crystalline polymorph of Claim 2, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 20.3.
5. A process for preparing the crystalline polymorph of Claim 2, comprising:
 - (a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 1:1 EtOH:water; and
 - (b) recrystallizing the solid to prepare Form A.
6. The crystalline polymorph of Claim 1, wherein the polymorph is Form B.
7. The crystalline polymorph of Claim 6, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.3) at about 9.9 and 25.5.
8. A process for preparing the crystalline polymorph of Claim 6, comprising:
 - (a1) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E with a solvent selected from MeOH, or
 - (a2) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from MeOH, acetone and DCM, or
 - (a3) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C/G mixture with a solvent selected from EtOH, or
 - (a4) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A with a solvent selected from IPA,
 - (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and the solvent, and

- (c) recrystallizing the solid to prepare Form B; or
 - (d1) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and ACN, or
 - (d2) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and THF, and
 - (e) recrystallizing the solid to prepare Form B; or
 - (f) heating *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, and
 - (g) recovering the solid to prepare Form B.
9. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Methanol.
 10. The crystalline polymorph of Claim 9, wherein said polymorph has an XRPD pattern substantially the same as Figure 2.
 11. The crystalline polymorph of Claim 9, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 10.0.
 12. A process for preparing the crystalline polymorph of Claim 6, comprising:
 - (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine with MeOH;
 - (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MeOH; and
 - (c) recrystallizing the solid to prepare Form B Methanol.
 13. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Ethanol.
 14. The crystalline polymorph of Claim 13, wherein said polymorph has an XRPD pattern substantially the same as Figure 3.
 15. The crystalline polymorph of Claim 13, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 25.4.
 16. A process for preparing the crystalline polymorph of Claim 13, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C/G mixture with EtOH;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and EtOH; and

(c) recrystallizing the solid to prepare Form B Ethanol.

17. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Isopropyl Alcohol.

18. The crystalline polymorph of Claim 17, wherein said polymorph has an XRPD pattern substantially the same as Figure 4.

19. The crystalline polymorph of Claim 17, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 16.9.

20. A process for preparing the crystalline polymorph of Claim 17, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A with IPA;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and IPA; and

(c) recrystallizing the solid to prepare Form B Isopropyl Alcohol.

21. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Acetonitrile.

22. The crystalline polymorph of Claim 21, wherein said polymorph has an XRPD pattern substantially the same as Figure 5.

23. The crystalline polymorph of Claim 21, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 25.7.

24. A process for preparing the crystalline polymorph of Claim 21, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and ACN; and

(b) recrystallizing the solid to prepare Form B Acetonitrile.

25. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Acetone.

26. The crystalline polymorph of Claim 25, wherein said polymorph has an XRPD pattern substantially the same as Figure 6.

27. The crystalline polymorph of Claim 25, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 9.9.

28. A process for preparing the crystalline polymorph of Claim 25, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and acetone;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and acetone; and

(c) recrystallizing the solid to prepare Form B Acetone.

29. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Dichloromethane.

30. The crystalline polymorph of Claim 29, wherein said polymorph has an XRPD pattern substantially the same as Figure 7.

31. The crystalline polymorph of Claim 29, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 16.9.

32. A process for preparing the crystalline polymorph of Claim 29, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DCM;

(b) creating a solution with the *N*4-(4-[1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DCM; and

(c) recrystallizing the solid to prepare Form B Dichloromethane.

33. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Tetrahydrofuran.

34. The crystalline polymorph of Claim 33, wherein said polymorph has an XRPD pattern substantially the same as Figure 8.

35. The crystalline polymorph of Claim 33, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 25.4.

36. A process for prepping the crystalline polymorph of Claim 33, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and THF; and

(b) recrystallizing the solid to prepare Form B Tetrahydrofuran.

37. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Anhydrous.

38. The crystalline polymorph of Claim 37, wherein said polymorph has an XRPD pattern substantially the same as Figure 9.

39. The crystalline polymorph of Claim 37, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 9.9.

40. A process for preparing the crystalline polymorph of Claim 37, comprising:

(a) heating *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B; and

(b) recovering the solid to prepare Form B Anhydrous.

41. The crystalline polymorph of Claim 1, wherein the polymorph is Form C.

42. The crystalline polymorph of Claim 41, wherein said polymorph has an XRPD pattern substantially the same as Figure 10.

43. The crystalline polymorph of Claim 41, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 5.0.

44. A process for preparing the crystalline polymorph of Claim 41, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and 2-methoxyethanol;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 2-methoxyethanol; and

(c) recrystallizing the solid to prepare Form C.

45. The crystalline polymorph of Claim 1, wherein the polymorph is Form D.

46. The crystalline polymorph of Claim 45, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.3) at about 8.0 and 12.7.

47. A process for preparing the crystalline polymorph of Claim 45, comprising:

(a1) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from EtOAc, dioxane and propyl acetate, or

(a2) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and a solvent selected from acetone and propyl acetate, and

(b) recrystallizing the solid to prepare Form D.

48. The crystalline polymorph of Claim 45, wherein the polymorph is Form D Ethyl Acetate.

49. The crystalline polymorph of Claim 48, wherein said polymorph has an XRPD pattern substantially the same as Figure 11.

50. The crystalline polymorph of Claim 48, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 8.0.

51. A process for preparing the crystalline polymorph of Claim 48, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and EtOAc; and

(b) recrystallizing the solid to prepare Form D Ethyl Acetate.

52. The crystalline polymorph of Claim 45, wherein the polymorph is Form D Dioxane.

53. The crystalline polymorph of Claim 52, wherein said polymorph has an XRPD pattern substantially the same as Figure 12.

54. The crystalline polymorph of Claim 52, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 19.5.

55. A process for preparing the crystalline polymorph of Claim 52, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and dioxane; and

(b) recrystallizing the solid to prepare Form D Dioxane.

56. The crystalline polymorph of Claim 45, wherein the polymorph is Form D Acetone.

57. The crystalline polymorph of Claim 56, wherein said polymorph has an XRPD pattern substantially the same as Figure 13.

58. The crystalline polymorph of Claim 56, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 8.0.

59. A process for preparing the crystalline polymorph of Claim 56, comprising:

- (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and acetone; and
 - (b) recrystallizing the solid to prepare Form D Acetone.
60. The crystalline polymorph of Claim 45, wherein the polymorph is Form D Propyl Acetate.
61. The crystalline polymorph of Claim 60, wherein said polymorph has an XRPD pattern substantially the same as Figure 14.
62. The crystalline polymorph of Claim 60, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 8.0.
63. A process for preparing the crystalline polymorph of Claim 60, comprising:
- (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and propyl acetate; and
 - (b) recrystallizing the solid to prepare Form D Propyl Acetate.
64. The crystalline polymorph of Claim 1, wherein the polymorph is Form E.
65. The crystalline polymorph of Claim 64, wherein said polymorph has an XRPD pattern substantially the same as Figure 15.
66. The crystalline polymorph of Claim 64, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 16.1.
67. A process for preparing the crystalline polymorph of Claim 64, comprising:
- (a) mixing 1-(4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea in THF under basic conditions;
 - (b) adding water to the mixture to form an oil of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine;
 - (c) recovering the product as *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E.
68. The crystalline polymorph of Claim 1, wherein the polymorph is Form F.
69. The crystalline polymorph of Claim 68, wherein said polymorph has an XRPD pattern substantially the same as Figure 16.
70. The crystalline polymorph of Claim 68, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 16.6.

71. A process for preparing the crystalline polymorph of Claim 68, comprising:
- (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and ethyl acetate; and
 - (b) recrystallizing the solid to prepare Form F.
72. The crystalline polymorph of Claim 1, wherein the polymorph is Form G.
73. The crystalline polymorph of Claim 72, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.3) at about 7.8 and 23.2.
74. A process for preparing the crystalline polymorph of Claim 72, comprising:
- (a1) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and 20:80 THF:water, or
 - (a2) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from isopropyl acetate and MIBK, and
 - (b) recrystallizing the solid to prepare Form G; or
 - (c) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and tetrahydrofuran,
 - (d) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF, and
 - (e) recrystallizing the solid to prepare Form G.
75. The crystalline polymorph of Claim 72, wherein the polymorph is Form G hemi-Tetrahydrofuran.
76. The crystalline polymorph of Claim 75, wherein said polymorph has an XRPD pattern substantially the same as Figure 17.
77. The crystalline polymorph of Claim 75, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.1.
78. A process for preparing the crystalline polymorph of Claim 75, comprising:
- (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and 20:80 THF:water; and
 - (b) recrystallizing the solid to prepare Form G hemi-Tetrahydrofuran.

79. The crystalline polymorph of Claim 72, wherein the polymorph is Form G mono-Tetrahydrofuran.

80. The crystalline polymorph of Claim 79, wherein said polymorph has an XRPD pattern substantially the same as Figure 18.

81. The crystalline polymorph of Claim 79, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 23.1.

82. A process for preparing the crystalline polymorph of Claim 79, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and tetrahydrofuran;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF; and

(c) recrystallizing the solid to prepare Form G mono-Tetrahydrofuran.

83. The crystalline polymorph of Claim 72, wherein the polymorph is Form G Isopropyl Acetate.

84. The crystalline polymorph of Claim 83, wherein said polymorph has an XRPD pattern substantially the same as Figure 19.

85. The crystalline polymorph of Claim 83, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 23.4.

86. A process for preparing the crystalline polymorph of Claim 83, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and isopropyl acetate; and

(b) recrystallizing the solid to prepare Form G Isopropyl Acetate.

87. The crystalline polymorph of Claim 72, wherein the polymorph is Form G Methyl Isobutyl Ketone.

88. The crystalline polymorph of Claim 87, wherein said polymorph has an XRPD pattern substantially the same as Figure 20.

89. The crystalline polymorph of Claim 87, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 23.3.

90. A process for preparing the crystalline polymorph of Claim 87, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-

(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MIBK; and

(b) recrystallizing the solid to prepare Form G Methyl Isobutyl Ketone.

91. The crystalline polymorph of Claim 1, wherein the polymorph is Form H.

92. The crystalline polymorph of Claim 91, wherein said polymorph has an XRPD pattern substantially the same as Figure 21.

93. The crystalline polymorph of Claim 91, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 11.2.

94. A process for preparing the crystalline polymorph of Claim 91, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MTBE; and

(b) recrystallizing the solid to prepare Form H.

95. The crystalline polymorph of Claim 1, wherein the polymorph is Form I.

96. The crystalline polymorph of Claim 95, wherein said polymorph has an XRPD pattern substantially the same as Figure 22.

97. The crystalline polymorph of Claim 95, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 7.2.

98. A process for preparing the crystalline polymorph of Claim 95, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and xylene; and

(b) recrystallizing the solid to prepare Form I.

99. The crystalline polymorph of Claim 1, wherein the polymorph is Form J.

100. The crystalline polymorph of Claim 99, wherein said polymorph has an XRPD pattern substantially the same as Figure 23.

101. The crystalline polymorph of Claim 99, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 17.0.

102. A process for preparing the crystalline polymorph of Claim 99, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 2-methoxyethanol; and

(b) recrystallizing the solid to prepare Form J.

103. The crystalline polymorph of Claim 1, wherein the polymorph is Form K.
104. The crystalline polymorph of Claim 103, wherein said polymorph has an XRPD pattern substantially the same as Figure 24.
105. The crystalline polymorph of Claim 103, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 22.8.
106. A process for preparing the crystalline polymorph of Claim 103, comprising:
- (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DME; and
 - (b) recrystallizing the solid to prepare Form K.
107. The crystalline polymorph of Claim 1, wherein the polymorph is Form L.
108. The crystalline polymorph of Claim 107, wherein said polymorph has an XRPD pattern substantially the same as Figure 25.
109. The crystalline polymorph of Claim 107, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 17.0.
110. A process for preparing the crystalline polymorph of Claim 107, comprising:
- (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MeOAc; and
 - (b) recrystallizing the solid to prepare Form L.
111. The crystalline polymorph of Claim 1, wherein the polymorph is Form M.
112. The crystalline polymorph of Claim 111, wherein said polymorph has an XRPD pattern substantially the same as Figure 26.
113. The crystalline polymorph of Claim 111, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 9.0.
114. A process for preparing the crystalline polymorph of Claim 111, comprising:
- (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol and 1:1 THF:water; and
 - (b) recrystallizing the solid to prepare Form M.
115. The crystalline polymorph of Claim 1 wherein the polymorph is Form N.

116. The crystalline polymorph of Claim 115, wherein said polymorph has an XRPD pattern substantially the same as Figure 27.

117. The crystalline polymorph of Claim 115, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 22.9.

118. A process for preparing the crystalline polymorph of Claim 115, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol and a solution of 1% sodium carboxymethyl cellulose, 0.1% Tween® in water; and

(b) recrystallizing the solid to prepare Form N.

119. The crystalline polymorph of Claim 1, wherein the polymorph is Form O.

120. The crystalline polymorph of Claim 119, wherein said polymorph has an XRPD pattern substantially the same as Figure 28.

121. The crystalline polymorph of Claim 119, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 11.2.

122. A process for preparing the crystalline polymorph of Claim 119, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran with THF;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF; and

(c) recrystallizing the solid to prepare Form O.

123. The crystalline polymorph of Claim 1, wherein the polymorph is Form P.

124. The crystalline polymorph of Claim 123, wherein said polymorph has an XRPD pattern substantially the same as Figure 29.

125. The crystalline polymorph of Claim 123, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 23.5.

126. A process for preparing the crystalline polymorph of Claim 123, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Tetrahydrofuran with water; and

(b) recrystallizing the solid to prepare Form P.

127. A pharmaceutical composition comprising a compound of Claim 1, and a pharmaceutically acceptable carrier or excipient.